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The Role of Gut Microbiota Urease in the Host With Liver Disease
Abstract
Significant metabolic interactions exist between the gut microbiota and the mammalian host, one prime
example of which is nitrogen metabolism. In the colon, bacterial urease hydrolyzes host-derived urea into
carbon dioxide and ammonia. Colonic ammonia can subsequently be absorbed by the host or utilized by
the gut microbiota for additional nitrogen metabolism. In patients with liver disease such as cirrhosis and
congenital urea cycle disorders, hepatic abnormalities prevent the normal processing of ammonia,
leading to hyperammonemia and hepatic encephalopathy (HE). Although circulating ammonia levels are
correlated with damage to the central nervous system, the pathogenesis of HE is complex and not fully
elucidated, hindering progress in treatment. Current treatment options including antibiotics, lactulose, and
a low protein diet (LPD) are complicated by issues such as side effects, concerns of safety and efficacy in
long-term use, and poor adherence. Our goal is to develop a safe, durable, and efficacious treatment for
HE through the inoculation of a urease-free bacterial consortium. We show that we are able to engineer
the gut microbiota to reduce fecal urease activity and ammonia levels in mice. Depletion of the
endogenous gut microbiota
followed by transplantation with Altered Schaedler Flora (ASF), a defined consortium of eight murine gut
commensal bacteria with minimal urease gene content, established a persistent new community that
exhibited long-term reduction in fecal urease activity and fecal ammonia production. ASF transplantation
was associated with a decrease in morbidity and mortality in the thioacetamide (TAA) murine model of
hepatic injury and fibrosis. Although the ASF consortium demonstrated reduced resilience in response to
dietary stress, ASF transplantation led to further reductions in fecal ammonia on a LPD without
exacerbating host metabolic dysfunction. These findings point to the potential use of a human ureasefree bacterial consortium to alter clinical management and outcome in HE. Furthermore, they provide
proof of concept that microbiota transplantation with a defined microbial consortium can lead to durable
metabolic changes with therapeutic utility.
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ABSTRACT
THE ROLE OF GUT MICROBIOTA UREASE IN THE HOST WITH LIVER DISEASE
Ting-Chin David Shen
Gary D. Wu

Significant metabolic interactions exist between the gut microbiota and the
mammalian host, one prime example of which is nitrogen metabolism. In the colon,
bacterial urease hydrolyzes host-derived urea into carbon dioxide and ammonia. Colonic
ammonia can subsequently be absorbed by the host or utilized by the gut microbiota for
additional nitrogen metabolism. In patients with liver disease such as cirrhosis and
congenital urea cycle disorders, hepatic abnormalities prevent the normal processing of
ammonia, leading to hyperammonemia and hepatic encephalopathy (HE). Although
circulating ammonia levels are correlated with damage to the central nervous system,
the pathogenesis of HE is complex and not fully elucidated, hindering progress in
treatment. Current treatment options including antibiotics, lactulose, and a low protein
diet (LPD) are complicated by issues such as side effects, concerns of safety and
efficacy in long-term use, and poor adherence. Our goal is to develop a safe, durable,
and efficacious treatment for HE through the inoculation of a urease-free bacterial
consortium. We show that we are able to engineer the gut microbiota to reduce fecal
urease activity and ammonia levels in mice. Depletion of the endogenous gut microbiota
followed by transplantation with Altered Schaedler Flora (ASF), a defined consortium of
eight murine gut commensal bacteria with minimal urease gene content, established a
persistent new community that exhibited long-term reduction in fecal urease activity and
fecal ammonia production. ASF transplantation was associated with a decrease in
morbidity and mortality in the thioacetamide (TAA) murine model of hepatic injury and
fibrosis. Although the ASF consortium demonstrated reduced resilience in response to
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dietary stress, ASF transplantation led to further reductions in fecal ammonia on a LPD
without exacerbating host metabolic dysfunction. These findings point to the potential
use of a human urease-free bacterial consortium to alter clinical management and
outcome in HE. Furthermore, they provide proof of concept that microbiota
transplantation with a defined microbial consortium can lead to durable metabolic
changes with therapeutic utility.
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CHAPTER 1. Introduction	
  

1.1 The gut microbiota and its metabolic interactions with the mammalian host
The human gastrointestinal tract is home to approximately 100 trillion
microorganisms, which exceed the total number of human cells by ten-fold1. The
biomass reaches up to 1012 cells per gram in the distal colon, making it one of the most
densely populated microbial habitats on earth2. This microbial community is known as
the gut microbiota, and it comprises ~500-1000 bacterial species along with fungi,
viruses, and archaea3. The microbes and their genomes, collectively known as the gut
microbiome, significantly impact various host physiologic processes, including nutrition
and metabolism4, 5, immune regulation6, inflammation and cancer7, 8, and even
neurodevelopment and behavior9. They perform these functions through mutualistic
interactions with the host, mediated primarily by the exchange of metabolites derived
from microbial and/or host metabolism. Specific metabolites may be produced by
specific microbes, the presence of which may thus be essential. But different microbes
may have evolved similar functions through divergent pathways, leading to functional
overlap or even a competitive relationship with one another for limited environment and
resources. Over the past few decades, the scientific community has seen a dramatic
increase in our knowledge of the composition and function of the gut microbiome. This
was made possible largely through technological advancements in culture-independent
methods for isolating and identifying microbes (e.g. 16S rRNA gene sequencing) as well
laboratory and computational methods to characterize their functions (e.g. gnotobiotic
mice and gene network association studies). Nevertheless, the future challenges of this
field lie in our ability to identify specific microbes and/or their functions associated with
particular diseases and to develop methods to modulate their unwanted effects. One
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approach would be to replace these “pathogenic” microbes with “beneficial” microbes
targeted toward specific biological processes without impairing other physiological
functions. This dissertation represents the work of a series of experiments designed to
test the feasibility and efficacy of such an approach. We replaced the endogenous gut
microbiota in mice with a defined bacterial consortium that lacks the bacterial enzyme
urease, which hydrolyzes host-derived urea to carbon dioxide and ammonia in the colon
(see Section 1.2). We hypothesized that such a bacterial consortium would decrease
colonic ammonia production and alter host nitrogen metabolism, with the durability of its
effects dependent upon the resilience of the bacterial consortium to environmental
perturbations such as dietary changes.
A large body of scientific literature supports the important role that the gut
microbiota plays in host metabolism. As one example, the gut microbiota is thought to
contribute the rising epidemic of metabolic diseases such as diabetes and obesity in the
developed world10. Pioneering work involving obese individuals and genetically obese
mice (ob/ob) found that the obese phenotype is associated with changes in the relative
abundance of two dominant bacterial phyla, Bacteroidetes and Firmicutes, whereby
Bacteroidetes were found to be decreased and Firmicutes increased11,

12

. Using

metagenomic and biochemical analyses, the investigators demonstrated that the
microbiome associated with the obese phenotype had an increased capacity to harvest
energy from the diet. Furthermore, by colonizing germ-free mice with the gut microbiota
of an ob/ob mouse and showing that it led to a greater increase in total body fat than
with the gut microbiota of its lean littermate, they demonstrated that these effects were
transmissible. Similar findings were reproduced by transplanting the gut microbiota of
human twins discordant for obesity into germ-free mice13. Conversely, by transplanting
the gut microbiota of Malawian twins discordant for kwashiorkor into germ-free mice, a
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form of severe acute malnutrition, the same group of investigators demonstrated that the
combination of a

Malawian diet and the kwashiorkor microbiome produced marked

weight loss in mice accompanied by perturbations in amino acid, carbohydrate, and
intermediary metabolism14. These finding strongly implicate the role that the gut
microbiota plays in host nutrition and metabolism by affecting energy extraction.
Three important classes of biological molecules illustrate the dynamic and
complex metabolic interactions between the mammalian host and its gut microbiota: bile
acids, short chain fatty acids (SCFAs), and choline. The primary bile acids, cholic acid
and chenodeoxycholic acid, are synthesized in the liver from cholesterol. Primary bile
acids are generally conjugated to glycine and taurine in the liver, stored in the
gallbladder, and then secreted into the small intestine in order to facilitate the digestion
and absorption of dietary fats and fat-soluble vitamins. Upon reaching the terminal ileum,
approximately 90-95% of the bile acids are reabsorbed across the intestinal epithelium
and recycled to the liver, completing the enterohepatic cycle 5-15 times daily5. However,
the remainder 5-10% of conjugated primary bile acids are either deconjugated by the
small intestinal bacteria to produce secondary bile acids such as deoxycholic acid (from
cholic acid) and lithocholic acid (from chenodeoxycholic acid) or lost in the feces4.
Bacteria that deconjugate primary bile acids to form secondary bile acids are generally
anaerobic bacteria of the genera Bacteroides, Eubacterium, and Clostridium5. Both
primary bile acids and secondary bile acids can act as signaling molecules by binding to
cellular receptors such as the farnesoid X receptor (FXR, activated by primary bile acids)
and G-protein-coupled-receptor (GPCR) TGR5 (activated by secondary bile acids) with
various downstream effects. FXR and TGR5 both affect glucose metabolism, but FXR
impairs glucose homeostasis, while TGR5 improves glucose homeostasis4. Circulation
of primary and secondary bile acids throughout the body with activation of FXR and
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TGR5 in peripheral organs can also affect overall host metabolism. For example, TGR5
activation in brown adipose tissue and muscle can increase energy expenditure and
ameliorate diet-induced obesity. The gut microbiota may thus modulate obesity and type
2 diabetes through its effects on lipid and glucose metabolism by altering the
composition of the bile acid pool and FXR and TGR5 signaling.
As opposed to bile acids that are primarily produced by the liver, SCFAs such as
acetate, butyrate, and propionate are products of complex carbohydrate fermentation by
colonic bacteria. Certain bacterial species, including B. thetaiotaomicron and
Bacteroides ovatus, contain more glycosidases and lyases than humans and thereby are
able to metabolize nearly all the glycans in dietary fiber4. SCFAs perform a variety of
functions. Butyrate serves as an important energy substrate for the colonic epithelium,
where it can also affect proliferation, differentiation, and modulation of gene expression
by inhibiting histone deacetylase4. Acetate and propionate can reach various organs
through the bloodstream and serve as substrates for lipogenesis and gluconeogenesis
as well as regulate different gene expressions by binding to GPCRs GPR41 and
GPR435. The end-organ effects of SCFAs through GPCRs depend on the cell type. For
example, SCFAs can modulate secretion of the hormone glucagon-like peptide-1 (GLP1) through effects on enteroendocrine L-cells in the distal small intestine and colon,
thereby improving insulin secretion5. On the other hand, SCFAs suppress inflammation
in neutrophils through GPR43 signaling. As acids, SCFAs can further lower pH in the
colonic luminal environment and affect microbiota composition and gut motility.
Unlike bile acids and SCFAs, choline is predominantly obtained from the diet in
foods such as red meat and eggs, although it can also be synthesized by the host4.
Choline is an essential component of the cell membrane, and it is primarily metabolized
in the liver, where it functions in lipid metabolism and the synthesis of very-low-density
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lipoprotein. The gut microbiota can metabolize dietary choline to produce trimethylamine
(TMA), which is further metabolized in the liver by the flavine monooxygenase system to
produce trimethylamine-N-oxide (TMAO), shown to be associated with the development
of atherosclerosis and cardiovascular diseases5. Both SCFAs and choline are discussed
further in Section 1.5.

1.2 Mammalian nitrogen metabolism and the significance of bacterial urease
As a key component of amino acids and nucleic acids, nitrogen is essential to
life. The body obtains most of its nitrogen through dietary protein intake, which are
hydrolyzed into peptides and amino acids by proteases and peptidases in the
gastrointestinal tract15. Most of the amino acids and peptides are absorbed into the body
via specialized transporters in the intestinal epithelium, but significant amounts of
undigested dietary as well as endogenous proteins (e.g. gastric and pancreatic
secretions, sloughed intestinal epithelial cells) enter the colon16, where they serve as
nitrogenous substrates for the colonic microbiota17. The absorbed amino acids can
function as building blocks for enzymes that catalyze critical cellular and molecular
processes in the body or undergo alternative metabolic pathways to act as precursors
for purines, pyrimidines, neurotransmitters, hormones, and other nitrogen-containing
compounds15. The catabolism of nitrogenous compounds, in particular amino acids,
results in the formation of ammonia, which can be toxic to the central nervous system if
elevated above normal (see Section 1.3). As a result, ammonia is generally combined
with glutamate to form glutamine via glutamine synthetase for transport in the blood18.
Circulating glutamine is subsequently deaminated by glutaminase to regenerate
glutamate and free ammonia in the liver and the kidneys.
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To dispose of excess nitrogen in the form of ammonia, the body utilizes a series
of enzymatically-mediated reactions known as the urea cycle to convert ammonia into
urea, CO(NH2)2, a non-toxic waste product. One nitrogen of the urea molecule is derived
from ammonia, and the other nitrogen is derived from aspartate; the carbon and oxygen
are derived from CO2. The urea cycle consists of five reactions involving five enzymes,
two of which are mitochondrial and three are cytosolic19. The urea cycle begins with 1)
the formation of carbamoyl phosphate by carbamoyl phosphate synthetase I, which
requires N-acetylglutamate as an allosteric activator. The synthesis of N-acetylglutamate
from acetyl coenzyme A and glutamate by N-acetylglutamate synthase is thus often
considered the sixth reaction of the urea cycle. 2) The carbamoyl portion of carbamoyl
phosphate is combined with ornithine via ornithine transcarbamoylase to form citrulline.
3) Citrulline is then transported from the mitochondrion into the cytosol and combined
with aspartate to form argininosuccinate via argininosuccinate synthetase. 4)
Argininosuccinate is cleaved by argininosuccinate lyase to produce fumarate and
arginine. Finally, 5) arginase cleaves arginine to regenerate ornithine and form urea.
Since arginase occurs almost exclusively in the liver, only the liver can synthesize urea
by cleaving arginine, but other tissues such as the kidneys can synthesize arginine via
the above reactions. Hepatic urea is primarily transported via the bloodstream to the
kidneys for urinary excretion, but approximately 15-30% of hepatic urea enters the colon,
where it is hydrolyzed back into ammonia and carbon dioxide by the bacterial enzyme
urease20. Colonic ammonia is then 1) reabsorbed by the host for additional hepatic
nitrogen metabolism, 2) utilized by the gut microbiota to synthesize amino acids and
other nitrogenous compounds, or 3) excreted in the feces. Bacterial urease is thus
critical for colonic urea nitrogen utilization and recycling by the healthy host and the gut
microbiota. However, colonic ammonia production via bacterial urease activity can
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exacerbate conditions of hyperammonemia, such as hepatic encephalopathy (HE) in
cirrhosis and urea cycle disorders (see Section 1.3).
Urea and urease both represent important landmark molecules in the history of
scientific investigation. Urea was the first organic molecule synthesized, and urease from
jack bean was the first enzyme crystallized as well as the first enzyme shown to contain
nickel21. A variety of bacteria, fungi, plants, and invertebrates produce urease, but no
mammalian urease gene has been identified22, 23. Therefore, the hydrolysis of colonic
urea via urease activity is exclusively a function of the gut microbiome. By hydrolyzing
urea to carbon dioxide and ammonia, bacterial urease provides bacteria with their
preferred nitrogen substrate to synthesize amino acids, amines, indoles, and other
nitrogenous metabolites22,

24

. At the same time, bacterial urease can function as a

virulence factor and contribute to the development of pathogenic conditions such as HE,
nephrolithiasis, pyelonephritis, and peptic ulceration22. As one example, Helicobacter
pylori generates ammonia via urease to neutralize gastric acid, allowing it to colonize
and proliferate in the stomach and leading to the formation of peptic ulcer disease22.
Bacterial ureases are cytosolic enzymes with the exception of H. pylori urease,
which has both cytosolic and extracellular activity25. Most bacterial ureases are
composed of three subunits (encoded by ureA, ureB, and ureC), but the urease of
Helicobacter spp. is composed of two subunits (encoded by ureA and ureB) and has
been shown to form a dodecameric complex of repeating subunits. Nevertheless, the
homology of amino acid sequences in urease is highly conserved across bacterial
species25. The urease gene cluster contains 7-9 genes that consist of both structural and
accessory genes. Only one regulatory gene, ureR, has been identified and is found only
in those gene clusters inducible by urea (see below)25. Regulation of urease expression
mainly occurs by three mechanisms. Some bacteria express urease constitutively (e.g.
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Morganella morganii), some bacteria express urease in the presence of urea (e.g.
Proteus mirabilis), and still other bacteria express urease under nitrogen limiting
conditions (e.g. Klebsiella), which is controlled by a two-component nitrogen regulatory
system (see below)22, 25. Additionally, the urease of Streptococcus salivarus is reported
to be regulated by pH. Urease exhibits simple Michaelis-Menten-type kinetic behavior25.
No evidence for substrate inhibition or allosteric behavior has been detected, but there
are a number of urease inhibitors that act by competitive inhibition, including hydroxamic
acids, phosphoramidates, and thiols. Urease inhibitors have been used to prevent and/or
treat conditions such as urinary stones and peptic ulcer disease, but their therapeutic
role is largely limited by their significant side effects26.
As mentioned above, certain bacteria express urease under nitrogen limiting
conditions. This is activated by the nac gene product, Nac, which belongs to the LysR
family of regulatory proteins27. Nac itself does not respond to nitrogen availability but is
regulated by NtrBC, a two-component regulatory system that senses and responds to
nitrogen deprivation28. NtrB is a sensor histidine kinase, and NtrC is a response DNAbinding transcription factor. In the setting of nitrogen limitation (perceived by bacteria as
low

intracellular

glutamine

and

ammonia),

NtrB

phosphorylates

NtrC,

which

subsequently activates transcription of genes that encode proteins to generate
alternative nitrogen sources. These include scavenging and transport systems of
nitrogenous molecules (e.g. ammonia, amino acids), glutamine synthetase, and
catabolic

enzymes

of

nitrogenous

compounds29.

Furthermore,

NtrC

activates

transcription of relA to produce RelA, which synthesizes guanosine tetraphosphate
(ppGpp), mediator of the stringent response30. The stringent response is another
bacterial stress response system and affects a number of bacterial physiological
processes in the setting of environmental stress. In the setting of nitrogen deprivation,
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the stringent response promotes amino acid biosynthesis but inhibits translation and
nucleotide metabolism. Thus, Ntr and stringent response systems work synergistically to
increase nitrogen availability but inhibit cellular processes that promote bacterial
proliferation when environmental nitrogen is scarce.

1.3 The gut microbiota and bacterial urease in hepatic encephalopathy
As mentioned previously, colonic ammonia production via urea hydrolysis by
bacterial urease exacerbates conditions of hyperammonemia such as hepatic
encephalopathy (HE) in liver disease and congenital urea cycle disorders. HE manifests
as a spectrum of neurological and psychiatric dysfunctions that range from mild memory
impairment to confusion, coma, and brain edema, potentially leading to death. The
pathogenesis of HE is complex and remains to be fully elucidated, but ammonia has
long been implicated to play an important role. More recently, inflammation and oxidative
and/or nitrosative stress are also reported to contribute to the development of HE31.
Furthermore, there is evidence to suggest that alterations in the gut microbiota and their
metabolites

such

as

amino

acid

derivatives

(e.g.

indoles,

oxindoles,

false

neurotransmitters precursors) and endotoxins may be involved in HE32.
Ammonia is the best characterized neurotoxin in the pathogenesis of HE. Plasma
ammonia concentrations are elevated in approximately 90 percent of the patients with
HE, although levels do not always correlate with HE severity33, 34. In addition to host
catabolism of proteins and amino acids, the gut represents the primary source of
ammonia production in the body. This is due to both bacterial metabolism of nitrogenous
compounds (e.g. dietary and endogenous proteins and urea) in the small intestine and
colon as well as enterocyte metabolism of glutamine (see Section 1.2). Ammonia
produced in the gut enters the systemic circulation via the portal vein, which drains
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directly into the liver. A normal liver converts almost all of the ammonia into urea and/or
glutamine, but hyperammonemia can occur in liver disease and urea cycle disorders due
to decreased hepatic metabolism and/or portosystemic shunts32. Ammonia is generally
transported in the blood in the form of glutamine, which provides a nontoxic form of
storage and transport18. The formation of glutamine from glutamate and ammonia via
glutamine synthetase occurs primarily in the muscle and liver, which may be impaired in
the setting of chronic liver disease given muscle wasting and hepatic dysfunction, further
elevating circulating ammonia levels in the blood. Ammonia passes through the bloodbrain-barrier (BBB) to enter the central nervous system (CNS), where it leads to brain
edema and intracellular swelling due to the formation of glutamine within astrocytes, the
only cell type within the CNS that contains glutamine synthetase35. Indeed, one study
showed that inhibition of glutamine synthetase ameliorated brain swelling in rats infused
with ammonia36.
Since hyperammonemia leads to increased formation of glutamine in the brain, it
indirectly increases cerebral uptake of large neutral amino acids (LNAAs) by enhancing
the activity of the L-amino transporter at the BBB that exchanges glutamine in the brain
for LNAAs in the blood. LNAAs include both the aromatic amino acids (AAAs) and the
branched chain amino acids (BCAAs). In the setting of liver disease, there is increased
AAAs (i.e. phenylalanine, tryptophan, and tyrosine) relative to BCAAs (i.e. valine,
leucine, and isoleucine) due to increased muscle consumption of BCAAs to form
glutamate and decreased hepatic metabolism of AAAs18. Since both BCAAs and AAAs
utilize the L-amino transporter to enter the CNS, decreased BCAA concentrations leads
to increased transport of AAAs into the brain. AAAs not only serve as precursors to
catecholamines and serotonin that function as neurotransmitters, they can also form
false neurotransmitters such as octopamine, phenylethanolamine, and synephrine37.
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Normally AAAs are decarboxylated to form amines, which subsequently undergo
additional metabolism in the liver to form aldehydes. When hepatic function becomes
impaired, precursor AAAs and their amines are shunted away from aldehyde formation
and may enter the central nervous system to become locally β-hydroxylated into false
neurotransmitters and replace normal neurotransmitters38. Fischer et al. proposed that
the ratio of BCAA to AAA (valine + leucine + isoleucine) / (phenylalanine + tyrosine)
would be predictive of HE39. Indeed, numerous reports have verified that a decrease in
this ratio is associated with hepatic dysfunction40, 41. Based on this rationale, BCAAs
have been used to treat HE. In a meta-analysis that included 16 trials with 827
participants with HE, although treatment with BCAAs did not affect mortality, it
significantly improved HE symptoms42. Based on preliminary data in our lab, we have
also observed that altering the composition of the murine gut microbiota using a ureasedeficient bacterial consortium can affect host plasma amino acid homeostasis and
increase the BCAA/AAA ratio (see Future Directions). This suggests that in addition to
its effects on colonic ammonia production via bacterial urease activity, the gut microbiota
may modulate nitrogen flux leading to alterations in host and microbial amino acid
metabolism via urease-dependent mechanisms.
The gut microbiota has indeed been implicated to play a role in the pathogenesis
of HE. Perhaps the best evidence to support its pathogenic role comes from the efficacy
of HE treatments aimed to modulate the gut microbiota and/or its metabolites. In addition
to the use of BCAAs as described above, lactulose, polyethylene glycol (PEG),
antibiotics, and probiotic have been used to treat HE. Lactulose is a nonabsorbable
disaccharide that serves as a standard therapy for HE. It is fermented by bacteria into
short chain fatty acids, thereby acidifying the colonic environment and sequestering
colonic ammonia as ammonium ion, which is more easily excreted into the feces. There
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is also evidence to suggest that lactulose may function as a prebiotic to increase the
growth of beneficial bacteria such as Lactobacilli, curtailing the growth of harmful
urease-producing bacterial species43. Nevertheless, lactulose use is poorly tolerated due
to the induction of significant diarrhea, leading to poor adherence. A recent study
compared the efficacy of lactulose and PEG in the treatment of HE. PEG is a purgative
commonly used for constipation and/or preparation for colonoscopy. In the acute
hospitalized setting, cirrhotic patients randomly assigned to receive PEG showed more
improvement in HE after 24 hours than those who received lactulose based on a
standardized scoring algorithm44. This suggests that rapid catharsis of colonic ammonia
and/or other bacterial metabolites by PEG alone can be effective in the treatment of HE.
Nevertheless, the chronic use of PEG as a maintenance therapy for HE has not been
validated.
Rifaximin is a synthetic nonabsorbable antibiotic that has demonstrated
comparable efficacy to lactulose in the treatment of HE. The mechanism by which
rifaximin ameliorates HE is not well understood, as studies have found no significant
change in the composition or abundance of the gut microbiota after treatment with
rifaximin,

except

for

modest

decrease

in

Veillonellaceae

and

increase

in

Eubacteriaceae45. Nevertheless, rifaximin is associated with improved cognitive function
and endotoxemia in HE accompanied by alteration of gut bacterial associations with
metabolites, suggesting that its beneficial effects may be attributable to changes in
bacterial metabolic function. Alternatively, rifaximin may act through the alteration of the
small intestinal microbiota, the composition of which would not be well characterized in
studies focused on the examination of feces. Although rifaximin has demonstrated
adequate safety profile, the risk of bacterial resistance in long-term use remains a
concern. Other antibiotics used to treat HE such as aminoglycosides, metronidazole,
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and vancomycin are similarly limited by significant toxicity and/or concern for bacterial
resistance. Probiotics are used to treat HE based on the notion that they may modulate
the gut microbiota by decreasing pathogenic bacteria and/or urease activity. In mice, a
lactobacillus probiotic reduced ammonia levels and mortality after liver injury with
thioacetamide46. Several probiotics tested in humans with cirrhosis have reported
modest evidence of efficacy47, 48. While promising, studies of probiotic therapies have
suffered from methodological limitations, poor documentation of long-term effects, and
small effects on outcome. These findings motivate efforts to engineer resilient bacterial
communities that effectively and durably alters the gut microbiota to treat HE.

1.4 Fecal microbiota transplantation and use of defined bacterial consortia
With the rising incidence of Clostridium difficile infection (CDI) over the past few
decades, clinicians and researchers have sought new ways to treat this disease entity
that is frequently recurrent and refractory to standard antibiotic therapy. Fecal microbiota
transplantation (FMT) has proven to be highly effective in treating recurrent and/or
refractory CDI, with a cure rate over 90%49. This provides proof of principle that the
dysbiotic microbiota can be modified to treat disease. The use of donor fecal material to
treat disease is not a novel concept. Rather, it has been practiced for centuries. The
Chinese most likely began the earliest known use of fecal material to treat disease.
According to Chinese literary records, during the 4th century, a well-known traditional
Chinese medicine doctor named Ge Hong reported the use of human fecal suspension
given orally to treat food poisoning or severe diarrhea with positive results50. In 17th
century Europe, a German physician named Christian Paullini published a book called
Heilsame Dreck-Apotheke (Salutary Filth-Pharmacy) on the medical uses of human and
animal feces51. In the modern era, Eiseman et al. reported the successful treatment of
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pseudomembranous colitis using fecal enemas in 195852. The idea of transferring
gastrointestinal contents (i.e. transfaunation) has also been used for centuries in
veterinary medicine for indications such as treating chronic diarrhea in horses and
increasing resistance of newborn chicks to Salmonella infection49.
As opposed to the untargeted use of transferring entire microbial communities in
feces from donors to recipients, another approach is to create synthetic mixtures of
defined bacterial strains cultured in the laboratory to achieve targeted physiological
effects. In 1989, Tvede and Rask-Madsen reported the successful treatment of recurrent
CDI using a defined mixture of ten bacterial strains isolated from healthy human feces53,
representing the first known use of a defined bacterial mixture to treat disease. The
mixture contained facultative aerobic and anaerobic bacteria, including three strains of
Clostridia species, three strains of Bacteroides species, two strains of E. coli,
Streptococcus faecalis, and Peptostreptococcus productus. These strains were chosen
to replace bacteria found to be diminished and/or absent in CDI (e.g Bacteroides spp.)
and installing bacteria that inhibited C. difficile in vitro (e.g. R. productus, C.
bifermentans, and one E. coli strain). In 2013, Petrof et al. isolated 33 strains of
nonpathogenic bacteria from the stool of a healthy donor and named the bacterial
mixture “RePOOPulate,” which was used to successfully treat recurrent CDI in two
patients for at least six months54. Although RePOOPulate bacterial strains were rare at
baseline in the recipients prior to treatment, analysis of their stool samples at six-month
follow-up after treatment showed that RePOOPulate constituted more than 25% of the
gut microbiota. These findings demonstrate the efficacy, resiliency, and sustainability of
defined bacterial mixtures in achieving targeted physiological effects to treat disease.
The success of FMT and synthetic defined bacterial mixtures in the treatment of
CDI provides credence to the notion that other disease entities associated with dysbiosis
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may be treated with similar approaches. These include but are not limited to
inflammatory bowel disease55, metabolic syndrome4, 5, and even autism9. As discussed
in Section 1.1, researchers haven shown that the obese and lean phenotype can be
conferred to germ-free mice by transferring fecal microbiota from obese and lean human
donors, respectively13,

14

. However, it is unclear which bacterial strains and/or

combination of bacteria were responsible for the observed phenotype. Identifying
specific microbes and understanding their metabolic properties may be the next crucial
steps toward achieving the desired physiological effects, especially in the creation and
development of defined bacterial mixtures. In the case of CDI, different microbes may
utilize different mechanisms to curtail the growth of C. difficile, among which are
competitive niche exclusion, production of small molecules and/or antimicrobial peptides,
modulation of bile acid metabolism, and immune regulation49. The specific members in a
bacterial consortium and their metabolic properties required to suppress the growth of C.
difficile, however, remain unknown. In the case of HE, a bacterial consortium that lacks
urease activity would limit colonic urea hydrolysis and ammonia production, potentially
ameliorating the clinical sequelae of hyperammonemia.
Defined mixtures of microbes have also been used in the creation and
development of gnotobiotic mice56. One such example is Altered Schaedler Flora (ASF).
The original Schaedler Flora was created by Russell W. Schaedler in the 1970s to
colonize germfree mice with bacteria isolated from conventional mice to restore cecal
morphology and enhance murine health. The chosen bacterial strains were primarily
aerobic bacteria or less oxygen sensitive anaerobes that were easy to culture, consisting
of the following: Escherichia coli var. mutabilis, Streptococcus faecalis, Lactobacillus
acidophilus, Lactobacillus salivarius, group N Streptococcus, Bacteroides distasonis, a
Clostridium sp., and an EOS fusiform bacterium57. In 1978, the National Cancer Institute
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revised and standardized the Schaedler Flora (renamed “Altered Schaedler Flora”) by
keeping four of the original bacterial strains (the two lactobacilli, B. distasonis, and the
EOS fusiform bacterium) while replacing the other four bacterial strains with a spiralshaped bacterium and three new fusiform EOS bacteria57, 58. ASF has now been used
for decades by commercial mouse vendors to colonize rodent colonies and enhance the
health of immunodeficient mouse strains. We found that ASF is low urease activity,
making it useful as a prototype consortium for studies of metabolic engineering
described to treat HE (see Chapter 2).
The use of FMT and synthetic microbial mixtures for the treatment of diseases
entail preparation of the gut environment for proper inoculation and colonization of the
transplanted bacterial species. In the case of CDI, there is generally antecedent use of
antibiotics that have already disrupted the endogenous microbiota, leading to dysbiosis,
proliferation of C. difficile, and subsequent replacement and suppression of C. difficile by
the transplanted microbiota. This is not necessarily the case for other disease
conditions. One reason that current generation of probiotics may not effectively or
sustainably replace the endogenous microbiota is because of the large endogenous
biomass already present in the gut environment, occupying niches and preventing the
effective colonization by new bacterial taxa. Thereby, developing a systematic and
reproducible method to dramatically reduce the endogenous gut microbial load will be
crucial for the successful inoculation and engraftment of defined bacterial consortia in
the treatment of disease (see Chapter 2).

1.5 The impact of diet on the composition and function of the gut microbiota
To develop stable and resilient microbial communities that can exert durable and
targeted physiological effects, we must first understand how they respond to
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environmental stressors. Antibiotics and diet, in particular, have been shown to exert
strong effects on the composition and function of the gut microbiota. By depleting certain
endogenous bacterial populations, antibiotics can lead to dysbiosis. This predisposes to
the proliferation of pathogenic bacterial strains such as C. difficile as discussed
previously. Dietary changes, on the other hand, exert influences over the gut microbiota
by altering nutrient and substrate availabilities. By increasing substrates preferred by
one microbial species over another, diet not only alters the composition of the gut
microbiota, but also microbial metabolic functions as well as host physiological
responses. One example is the concept of enterotypes. Several studies have shown that
the ratio between two main genera in the human gut microbiota, Bacteroides and
Prevotella, is strongly dependent on diet. The relative abundance of Prevotella was
found to be high in populations that consumed a plant-based diet high in carbohydrates
and simple sugars, such as rural African village in Malawi and Venezuela59, 60. On the
other hand, the relative abundance of Bacteroides was found to be high in populations
that consumed more animal proteins and fats, such as the United States61,

62

.

Bacteroides and Prevotella may exhibit co-exclusion based on their taxonomic and
functional similarities55,

63

. Although other studies have challenged the concept of

enterotypes to suggest that it represents more of a gradient rather than distinct clusters
of taxonomic representations across populations, it nevertheless emphasizes the
importance of diet in shaping the gut microbiota55, 64. In Chapter 3, we will examine how
systemic nitrogen limitation in the setting of a low protein diet (LPD) can affect the
composition and function of a defined bacterial consortium with minimal urease activity.
This is relevant because bacterial urease is critical in host-gut microbiota nitrogen flux,
but also because a LPD is used clinically to treat conditions of hyperammonemia.
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Therefore, investigation of the stability and resilience of a urease-deficient bacterial
consortium in the setting of a LPD has significant clinical implications.
Exactly how significant and rapid are the effects that diet exerts on the gut
microbiota? In a controlled-feeding experiment, ten human subjects were randomized to
receive either a high-fat, low-fiber diet or a low-fat, high-fiber diet for ten days62. 16S
tagged sequencing analysis of fecal samples revealed significant inter-individual
differences that accounted for most of the variances in gut microbial composition. Over
the course of experiment, however, the study did not find a significant reduction in interindividual differences within the same diet group. This suggests that short-term dietary
changes do not overcome inter-individual differences in gut microbial composition.
Nevertheless, the study found that changes in gut microbiota from baseline were
detectable within 24 hours of initiating controlled feeding, indicating rapid effects from
the dietary interventions. Alterations in the composition of the human gut microbiota due
to dietary perturbations may be modest compared to those observed in rodents. In a
human study comparing the microbial composition between omnivores and vegans, the
differences were found to be a relatively modest65. On the other hand, in a recent murine
study, the investigators used either a low-fat, high-plant-polysaccharide diet or a high-fat,
high-sugar diet to examine the effects of dietary perturbations on the gut microbiota of
five inbred mouse strains, mice deficient for genes relevant to host-microbial
interactions, and >200 outbred mice66. The high-fat, high-sugar diet rapidly and
reproducibly altered the gut microbiota despite differences in host genotype, taking an
average of 3.5 days for each diet-responsive bacterial groups to reach a new steady
state.
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Specific dietary nutrients may affect the relative abundances of specific microbes
based on their metabolic properties and preferences. For example, the main
saccharolytic genera in the human gut microbiota include Bacteroides, Bifidobacterium,
Clostridium, Eubacterium, Lactobacillus, and Ruminococcus67. The most abundant
amino acid fermenting bacteria in the human small intestine include the genera
Clostridium, Bacillus-Lactobacillus-Streptococcus groups, and Proteobacteria, whereas
bacteria belonging to the genera Clostridium and Peptostreptococcus appear to be the
most prevalent species involved in amino acid fermentation in the large intestine68. In a
murine study, investigators generated gnotobiotic mice by inoculating ten sequenced
human bacterial strains into germfree mice then assessed the changes in species
abundance in response to systematic variations in four defined dietary ingredients
representing

four

macronutrients

(i.e.

casein=protein,

corn

oil=fat,

corn

starch=polysaccharide, and sucrose=simple sugar)69. Based on the responses, they
developed a statistical model that was able to predict over 60% of the variation in
species abundance caused by dietary changes and identify the dietary factor that best
explained the changes seen for each community member. For example, the abundances
of E. coli and C. symbiosum correlated with changes in the diet variables sucrose and
starch, respectively. They also found that total community biomass and the abundance
of each community member were best explained by changes in the diet variable casein,
potentially because a component of casein, likely amino acids and/or nitrogen,
influences the growth of the microbial community.
Dietary nutrients not only affect the composition of the gut microbiota, but also its
function and, in turn, microbial metabolites and the host metabolome. One prime
example is the fermentation of complex carbohydrates in the diet by the gut microbiota
to produce short-chain fatty acids (SCFAs) such as acetate, butyrate, and propionate as
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discussed in Section 1.1. Another example is bacterial metabolism of dietary lipid
phosphatidylcholine that is associated with the development of atherosclerosis and
increased risk for cardiovascular disease, also discussed in Section 1.170,

71

.

Furthermore, in a human study that examined gut microbiota composition and
metabolomics analyses between omnivores and vegans in an urban US population,
several important differences were found65. First, diet has a strong impact on the plasma
metabolome of omnivores and vegans, but the effect on the composition of the gut
microbiota was quite modest. Plasma metabolomes between omnivores and vegans
differed significantly, but the microbiota composition was not strongly associated with the
plasma metabolome. Second, the production of microbial metabolites from dietary
substrates is constrained by the composition of the gut microbiota. Unlike prior studies of
populations living in agrarian societies where increased SCFA levels have been
attributed to both increased consumption of indigestive carbohydrates and increased
polysaccharide-fermenting microbiota59, this study did not detect significant differences
in fecal SCFA levels between omnivores and vegans despite increased ingestion of
fermentable substrates in the latter. Although numerous studies have examined the
impact of dietary interventions involving alterations in carbohydrate and fat contents, the
effect of altering protein content is relatively under-investigated especially in light of its
importance in host and gut microbiota nitrogen metabolism. In Chapter 3, we will
discuss the impact of a low protein diet on the gut microbiota and host in terms of
nitrogen flux given relevance to the treatment of hyperammonemic inborn errors of
metabolism such as urea cycle disorders.
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CHAPTER 2. Engineering the Gut Microbiota to Treat Hyperammonemia

The contents of this chapter have been published as:
*Shen TC, *Albenberg L, Bittinger K, Chehoud C, Chen YY, Judge CA, Chau L,
Ni J, Sheng M, Lin A, Wilkins BJ, Buza EL, Lewis JD, Daikhin Y, Nissim I,
Yudkoff M, Bushman FD, Wu GD. Engineering the gut microbiota to treat
hyperammonemia. J Clin Invest. 2015 Jul 1;125(7):2841-50.
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determine the effects of ASF transplantation on neurobehavioral performance
and mortality in the thiocetamide murine model of hepatic injury and fibrosis
3) Biochemical assessment of fecal and plasma ammonia levels in all related
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4) Assistance with drafting and revising the relevant sections of the manuscript
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2.1 ABSTRACT
Engineering the gut microbiota for therapeutic modulation of host metabolism is
an emerging goal of microbiome research. In the intestine, bacterial urease converts
host-derived urea to ammonia and carbon dioxide, contributing to hyperammonemiaassociated neurotoxicity and encephalopathy in patients with liver disease. Here we
report engineering the gut microbiota in mice for therapeutic reduction of urease activity.
Depletion of the pre-existing gut microbiota followed by inoculation with Altered
Schaedler’s Flora (ASF), a defined consortium of 8 bacteria with minimal urease gene
content, established a persistent new community that exhibited long-term reduction in
fecal urease activity and ammonia production. ASF transplantation was associated with
decreased morbidity and mortality in a murine model of hepatic injury. These results
provide proof-of-concept that inoculation of a prepared host with a defined gut microbiota
can lead to durable metabolic changes with therapeutic utility.

2.2 INTRODUCTION
Dysbiosis, an abnormal and pathogenic state of the human microbiome, has
been implicated in inflammatory bowel diseases, atherosclerosis, obesity, diabetes,
colon cancer, and other diseases

1, 2

. Fecal microbiota transplantation (FMT) is highly

effective in the treatment of refractory Clostridium difficile infection (CDI), providing
proof-of-principle that a human disease can be treated by engineering the gut microbiota
3

, and further studies indicate that a healthy microbiota can prevent disease acquisition 4.
Bacteria residing in the human gut produce urease, the activity of which is

beneficial in healthy hosts but pathogenic in hosts with liver disease. Urea produced by
the liver as a waste product is both excreted in urine and transported into the colon,
where it is hydrolyzed by bacterial urease into carbon dioxide and ammonia. Ammonia is

	
  

27

then 1) utilized by the microbiota for protein synthesis, 2) reabsorbed by the host where
it is incorporated into the nitrogen pool by hepatic metabolism, or 3) excreted in the
feces. Mammalian genomes do not encode urease genes, so ammonia production
results from bacterial urease activity acting on host-produced urea

5, 6

. Ammonia is also

largely responsible for the alkaline pH of the colonic luminal environment, acting to buffer
the short chain fatty acids also produced by the microbiota. Systemic ammonia levels
are elevated in patients with liver injury, chronic liver disease, or urea cycle defects,
where hepatic abnormalities prevent the normal processing of ammonia delivered to the
liver from the intestinal tract. Circulating ammonia is correlated with damage to the
central nervous system in patients with chronic liver disease or inborn errors of
metabolism, resulting in hepatic encephalopathy (HE) 7, 8.
Current treatments for hepatic encephalopathy and hyperammonemia are
inadequate 8. Antibiotics traditionally used to treat hepatic encephalopathy, including
aminoglycosides and metronidazole, are limited by side effects and concerns for safety
including ototoxicity, nephrotoxicity, and peripheral neuropathy

9, 10

. Although rifaximin, a

minimally absorbed antibiotic, has shown efficacy in the treatment and prevention of
hepatic encephalopathy

11, 12

, potential development of antimicrobial resistance with

long-term use remains a concern. Lactulose is used to acidify feces and sequester
ammonia as ammonium, but lactulose is poorly tolerated, resulting in poor adherence

13

.

In a mouse-model of thioacetamide-induced liver injury, a lactobacillus probiotic has
been reported to reduce ammonia levels and mortality
been extended to human studies

15, 16

14

, but these benefits have not

. While promising, studies of probiotic therapies in

humans described to date have suffered from methodological limitations, did not
document long term effects, and showed consistently small effects on outcome,
motivating efforts to engineer more resilient and effective bacterial communities.
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Here we show that a synthetic microbial community lacking urease activity can
be installed in the gut to reduce the production of ammonia long-term and thereby
mitigate HE in a mouse model. For proof of concept studies, we used Altered
Schaedler’s Flora (ASF), which consists of eight murine gut commensal bacterial strains
that were assembled in the 1970s and standardized by the National Cancer Institute in
1978

17

. The strains were originally selected based on their persistence from generation

to generation in germ-free mice and their ability to restore the cecal morphology
comparable to that of conventional mice. The ASF community is innocuous, known to
have a beneficial effect of inducing immune tolerance

18

, and is used by commercial

mouse vendors to enhance the health of immunodeficient mouse strains. We found that
ASF is low in urease activity, making it useful for studies of metabolic engineering
described here. Mixed results have been reported regarding the transfer of conventional
microbiota between rodents, with some studies reporting successful transfer with
repetitive inoculation

19

but others that the use of antibiotics prevented transfer

20

. We

developed methods for purging the gut microbiota from normally colonized mice, then
transplanted in ASF by gavage. Transplantation of ASF was monitored longitudinally
using deep sequencing of DNA from fecal pellets, revealing highly efficient colonization
in properly prepared hosts. Over four weeks of monitoring, ASF was partially displaced
by selective colonization with environmental Firmicutes, reaching a new steady state, but
fecal ammonia levels remained low. The engineered gut community was tested in
thioacetamide (TAA) models of acute and chronic liver injury (Fig. 2-1A) where we show
that it reduced fecal ammonia levels, mortality, and neurobehavioral deficits. These
results show that transplantation of a minimal defined microbial community can alter
metabolism in a pre-determined fashion by establishing a new gut microbiome, resulting
in therapeutic benefits in disease models.
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Figure 2-1. Transferring ASF into a previously colonized murine host. (A) Diagram
of the experimental method. (B) Shotgun metagenomic analysis of stool from ASFcolonized animals used for gavage in this study. Proportions of the different ASF
lineages and other organisms are shown by the color code to the right. (C) Time course
of 16S rRNA gene copy number during oral antibiotic treatment (14 days, vancomycin
and neomycin) and upon discontinuing antibiotics on day 15 (n=3 per group). Asterisks
on left indicate p<0.0001 on Days 0-2 compared to average of Days 5-15 in ABX group.
Asterisks on right indicate p<0.05 between ABX and control group. Paired-sample t-test
and two-tailed Student’s t-test.

2.3 MATERIALS AND METHODS
Animals: Feces from CB17 SCID mice colonized with ASF (Taconic, Tarrytown NY)
were the source of ASF in transplantation experiments. Mice in this study were
maintained in standard SPF barrier facility and were fed irradiated AIN-76 (Research
Diets, 21% protein by kilocalories) chow. The non-irradiated diet experiment used
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Laboratory Rodent Diet 5001 containing 29% protein by kilocalories. For microbiota
transfer experiments, 0.1 g of feces was diluted 10-fold in PBS. Where indicated, germfree mouse recipients were purchased from Taconic as were conventionally-housed
Swiss Webster mice in the first experiment. All other experiments used either male or
female 8-week-old C57BL6 mice (Jackson Labs). Pre-treated conventional mice were
prepared for inoculation by the oral delivery of antibiotics in drinking water (1.125 g of
aspartame, 0.15 g of vancomycin, and 0.3 g of neomycin in 300 ml of sterile water) for
72 hours. During the final 12 hours water supply was exchanged with a 10% PEG
solution (Merck, Whitehouse NJ) and the mice were fasted. Mice were then inoculated
with feces by oral gavage daily for 5-7 days. Fecal pellets were collected during the
indicated time points for bacterial taxonomic and biochemical analyses.

DNA isolation, quantitative PCR, sequencing, and analysis: DNA was isolated from
stool as described

21, 22

. Bacterial 16S rRNA gene sequences were PCR amplified using

primers binding to the V1V2 region

21, 22

using bar coded primers

23, 24

.

Shotgun

metagenomic data was collected using the TruSeq library preparation method and an
Illumina HiSeq instrument. Sequence reads were quality controlled and analyzed using
the QIIME pipeline with default parameters

25

. Sequence data sets will be deposited at

the NCBI upon acceptance of this paper for publication.

Urease activity and ammonia assays: Fecal ammonia levels were determined using
an Ammonia Assay Kit (ab83360, Abcam, Cambridge, MA). Fecal pellets were
suspended in the assay buffer provided at a concentration of 1 mg/10 uL and centrifuged
at 13,000 x g for 10 minutes at room temperature to remove insoluble material.
Ammonia concentration was then determined according to the kit protocol.
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Fecal urease activity was measured by suspending fecal pellets in 0.5 mM
HEPES buffer. After sonication and centrifugation the supernatant was incubated for 30
minutes at 37°C with 1µCi

14

C-labeled urea (19.9 mCi/mmol, ARC-0150, American

Radiolabeled Chemicals, St. Louis, MO) in a sealed container. The air was purged into a
trap containing 2.5 mL of 0.2 M benzethonium hydroxide in methanol (82156, Sigma,
Milwaukee, WI) and

14

CO2 activity was quantified by liquid scintillation counting. A

standard curve was generated using purified E. coli urease (150 IU/mg, 22060744-1,
BioWorld, Dublin, OH).
The urease breath test was performed after a 4-hour fast by placing mice in a
sealed glass chamber. A total of 4 cc of air was withdrawn from the chamber using a
gas-tight syringe after 10 minutes and injected into 12 ml (gas-helium) Labco Exetainer
glass vials (438B, Labco Limited, Lampeter, UK) to establish a baseline CO2 level. The
mouse was then injected by tail vein with [13C]urea (150 µg/g body weight) (CLM-311-0,
Cambridge Isotope Labs, Inc., Andover, MA). Blood was collected 15 minutes postinjection to assess total urea and isotopic enrichment in [13C]urea. Enrichment in
expired air was measured at 30, 60, 120, 180, and 240 min following injection of labeled
urea. The 13CO2/12CO2 ratio was measured in gas samples with a Finnigan Delta Plus
isotope ratio-mass spectrometer (Thermo Fisher Scientific, Waltham, MA). A commercial
CO2 source (Airgas, Radnor, PA) was used as the standard. The measurement of
isotopic abundance in [13C]urea in plasma involves the elimination of CO2 from the
sample and the subsequent conversion of urea to CO2 with commercially available
urease 26.
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Induction of acute liver injury and hepatic fibrosis: Mice were given a single dose of
TAA at 600 mg/kg by IP injection in the high-dose TAA acute liver injury model. In the
low-dose TAA acute liver injury model, mice were given a single dose of TAA at 300
mg/kg by IP injection, with subsequent performance of the Y-maze neurobehavior test at
48 hours after TAA injection (see Neurobehavior test below). In the chronic liver fibrosis
model, all mice were given TAA by IP injection three times weekly, with initial dose 100
mg/kg that was decreased to 50 mg/kg during 1st week given mortality, then dose
escalation to 100 mg/kg during the 2nd week, 200 mg/kg during the 3rd week, 300 mg/kg
during the 4th week, and 400 mg/kg during the 5th to 7th week of TAA administration.

Neurobehavior test: The Y-maze test was conducted to assess the rodent’s memory
and spatial learning

27

. It consists of three identical and equally-spaced arms, and the

natural tendency of the mouse is to investigate a new arm of the maze rather than
returning to the one previously visited. A mouse with cognitive deficit would exhibit less
“spontaneous alternation,” defined as entering all three arms in three sequential arm
entries. Control mice typically exhibit >60% spontaneous alternation. In this experiment,
mice were allowed to habituate to the testing room in which there are no overt visual
cues for 30 minutes prior to testing. The maze was cleaned with 70% ethanol before
using and between trials to eliminate odor cues. A trial started when a mouse is released
into one arm of the maze (same arm for each mouse). As the mouse navigated the
maze, each arm entry was noted. At the end of the timed trial (8 minutes), total arm
entries are summed and spontaneous alternations are determined by the following
formula: % Spontaneous Alternation= [(Number of alternations) / (Total arm entries−2)]
×100. Trials were video recorded as well as graded during the procedure. Image
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analysis software was used to measure the total distance traveled during the trial for
each mouse.

Statistics: Results are expressed as means ± standard error of the mean (SEM).
Statistical significance among three or more groups was assessed by analysis of
variance (ANOVA). Two-tailed Student’s t-test and paired-sample t-test were used for
direct comparison between two groups and within group, respectively. Tukey’s test was
used to adjust for multiple comparisons. Kaplan-Meier survival curves were compared
using the Log-Rank Test. P < 0.05 was considered as statistically significant.

Study approval: All animal studies were performed with the approval of University of
Pennsylvania’s Institutional Animal Care and Use Committee.

2.4 RESULTS
Transplantation of ASF into previously colonized mice.
The original ASF was composed of eight bacterial strains. Over time, ASF has
been maintained in laboratory mice by fecal-oral transmission associated with cohousing
in gnotobiotic isolators. Thus the composition of the ASF donor material used here was
first characterized by DNA isolation and shotgun metagenomic sequencing (16.9 Gb).
Alignment to draft genome sequences of ASF strains

28

documented the presence of

seven of the eight original strains in our samples (Fig. 2-1B). Parabacteroides (ASF519)
was the predominant lineage present in pellets. Additional ASF strains consisted of
roughly even proportions of Clostridia (ASF356, ASF492, ASF500, ASF502) and
Mucispirillum schaedleri (ASF457), accompanied by low levels of Lactobacillus
(ASF361).

	
  

No high-quality read pairs mapped concordantly to strain ASF360.
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In

addition to ASF strains, 11% of reads mapped to the mouse genome, and a small
fraction of alignments mapped to probable artifacts including cloning vectors, metazoans
and additional bacteria. We conclude that the bacteria in our donor material were mostly
or entirely ASF strains.
To assess the persistence of ASF in mice housed under non-sterile conditions,
sequential fecal pellets were collected from ten ASF-colonized mice that were
transferred to conventional SPF housing, DNA was purified from pellets, and the
abundance and types of bacteria present assessed by QPCR and deep sequencing of
16S rRNA V1V2 gene segments (Supplementary Fig. 2-1). Copy numbers of 16S
sequences per gram of stool showed roughly similar abundance for ASF and
conventionally colonized mice. Six of the eight ASF strains were resolved at the depth of
sequencing performed. ASF519 (Parabacteroides) accounted for ~75% of sequence
reads at the time of transfer of the mice. After approximately 2 months under nonsterile
conditions, ASF519 remained the dominant taxon, and non-ASF taxa accounted for
almost half of the sequence reads. Evidently ASF lineages persisted but did not entirely
exclude other bacteria.
We reasoned that reduction of the endogenous microbiota would promote
transfer of ASF, so we investigated the response of conventional microbiota to the oral
delivery of two nonabsorbable antibiotics (ABX), neomycin and vancomycin. The 16S
rRNA gene copy number was reduced by ~4 logs within 72 hours of oral antibiotic
initiation (p<0.0001 for days 0, 1, and 2 compared to the mean of days 5-15), then
returned to baseline 5 days after discontinuing antibiotics (Fig. 2-1C; p=0.36 for
comparison of ABX versus control at day 21), paralleling previous studies 29, 30.
Fecal slurries obtained from ASF-colonized mice (Taconic, Germantown, NY)
were then gavaged into conventionally housed recipients for seven days following a 72-
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hour pre-treatment with oral antibiotics and a 12-hour intestinal purge using polyethylene
glycol (PEG; pretreatment with antibiotics and PEG termed “Prepared” henceforth). PEG
was used in our gut cleansing protocol because the use of a purgative will likely be
necessary to reduce bacterial load in the human intestinal tract due to high biomass. For
comparison, ASF transplants were carried out on conventional mice without
pretreatment and on germ-free mice. Mice that were treated with antibiotics and PEG,
and subsequently transplanted, showed normal numbers of bacteria by 16S QPCR copy
number within 10 days (data not shown).
Longitudinal fecal samples were analyzed by deep sequencing of 16S rRNA
gene tags, then the proportions of bacterial lineages detected plotted as heat maps,
where each row shows a bacterial lineage and each column a fecal specimen (Fig. 2-2).
Conventional mice that were not pretreated showed no increase in ASF lineages despite
ASF gavage (Fig. 2-2, “Conventional + ASF gavage”). A few preexisting lineages were
present that were indistinguishable from ASF using the V1V2 16S sequence window, but
these did not increase in abundance after ASF gavage. A second group of mice
(discussed above) were colonized with ASF from birth and then moved to the non-sterile
facility. These mice had high levels of ASF519 and detectable levels of four other ASF
strains (Fig. 2-2, “ASF-colonized”).
These groups were then compared to (1) germ-free mice gavaged with ASF and
(2) conventional mice pretreated with antibiotics and PEG and gavaged with ASF (Fig.
2-2, “Germ-free + ASF gavage” and “Prepared host + ASF gavage”). Prior to ASF
gavage, both the germ-free animals and antibiotic-treated animals showed high levels of
Lactococcus, a lineage found in high levels in mouse chow

29

, indicating that

endogenous gut bacteria were mostly or entirely absent. Gavage of these animals with
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ASF resulted in establishment of ASF lineages that persisted for the duration of the
sampling period. Communities were again dominated by ASF519.

Figure 2-2. Heat map showing the relative abundance of bacterial lineages over
time in ASF-colonized mice and controls. Rows indicate bacterial lineages as
annotated on the left. Relative abundance is indicated by the color code at the bottom of
the figure. Columns summarize sequencing results from individual fecal specimens.
Elapsed time in days is shown along the bottom. Groups studied are indicated at the top
of the heat map. These include (starting from the left): Conventional mice that were
gavaged with ASF stool without preparation (“Conventional + ASF gavage”); mice that
were ASF-colonized from birth, then transferred to a nonsterile SPF facility (“ASFcolonized”); mice that were germ-free, then gavaged with ASF (“germ free + ASF
gavage”); and conventional mice that were prepared by antibiotic and PEG treatment,
then gavaged with ASF (Prepared host + ASF gavage”).

Longitudinal evolution of the transplanted ASF community.
Persistence of the transplanted ASF community was quantified using segmental
regression, plotting time against the proportion of ASF in each sample (Fig. 2-3A).
Prepared ASF-transplanted mice or germ-free ASF-transplanted mice transferred to
nonsterile conditions were compared and found to behave similarly. Initially ASF
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comprised the majority of the community. After transfer, the proportion of ASF slowly
declined, becoming ~45% of the gut community after 34 days (Davies’ test for change in
slope p<0.001; 95% CI for break point was 27-41 days by segmented linear regression).
After 34 days, the proportion of ASF strains did not decrease for the duration of the
experiment (120 days; p=0.86). Comparisons of community membership using
unweighted UniFrac analysis of the 16S rRNA gene sequencing data showed non-ASF
lineages had colonized by day 14, and members persisted for the duration of the study
(Fig. 2-3B), although the final abundance of non-ASF lineages was not achieved until
about day 30 (Fig. 2-3A). Diversity of this new stable state measured by the Shannon
index approached that of the starting community (Fig. 2-3C). ASF519 (Parabacteroides)
was the main taxon persisting in both germ-free + ASF gavage and Prepared + ASF
gavage hosts after six weeks, comprising approximately 40% and 50% in each (Fig. 2-2).
As in humans, bacteria belonging to the Bacteroides genus were dominant taxa in
conventionally housed mice 31, 32.
The new lineages appearing after transplantation were specific (Fig. 2-4).
Members of the Bacteroidetes phylum did not recolonize after ASF transplantation,
suggesting that ASF519, a member of the closely related Parabacteroides genus, may
have occupied niches available to this group. Several Firmicutes lineages did colonize
over time, including lineages annotating as Oscillibacter, Clostridium, and “Other”
Firmicutes (mostly Order Clostridiales). Thus the community achieved a new steady
state containing both ASF and environmentally-acquired lineages.
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Figure 2-3. Development of a stable gut microbial community nucleated by
inoculation with ASF. (A) Segmented regression analysis of communities in mice that
were either germ-free or Prepared conventional mice subjected to ASF gavage. The yaxis shows the proportion of ASF lineages inferred from 16S rRNA gene tag
pyrosequencing data. The x-axis shows the number of days post transfer. Segmented
regression analysis showed two phases, indicating a slow decline in the ASF proportion
up to about day 30, followed by establishment of a new steady state with ~40% ASF
lineages. (B) PCoA ordination over time. Changes in community membership over time
were analyzed using unweighted Unifrac	
   33. The grey arrow indicates the progression of
time. (C) Shannon diversity of the gut microbiota over time in the four hosts described in
Fig. 2-2.
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Figure 2-4. Comparison of non-ASF sequence reads from either (A) Bacteroidetes
or (B) Firmicutes, illustrating selective repopulation with environmental Firmicutes.
Groups are color-coded and represent change over time.

ASF has minimal urease gene content and activity.
An analysis of the complete ASF genomes showed minimal presence of urease
genes. No urease genes were identified in the predominant Parabacteroides ASF519.
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Two ASF members contained urease genes, ASF492 and ASF361, but both were minor
members of the community after transplant (Fig. 2-2).
We then characterized urease activity. Urease activity was readily detectable in
pellets from conventionally housed mice but was undetectable in pellets from mice
colonized with ASF (Fig. 2-5A). Similar results were obtained with pellets from mice
treated with oral antibiotics that reduced bacterial load 10,000-fold (Fig. 2-5A).
Intravenous delivery of 13C-urea to quantify urease activity in vivo through the production
of 13CO2 in a breath test revealed minimal hydrolysis in ASF-colonized mice (Fig. 2-5B).
Transplantation of ASF into prepared hosts led to a reduction in fecal urease
activity lasting for at least 80 days (Fig. 2-5C). The novel community assembled after 30
days had low urease activity, even though new lineages became established in addition
to ASF (Fig. 2-2). Analysis of representative genomic sequences from these newly
established genera showed that Oscillibacter, Dorea, Enterococcus, and Roseburia do
not encode urease genes. Clostridium and the group annotating as “other” Firmicutes
(mostly Clostridiales), are mixed, with some representatives encoding urease genes
while others do not. It is unknown whether the newly proliferating organisms lacked
urease genes, or whether they encoded urease genes but expressed them at low levels.
Thus the net effect of ASF colonization, together with establishment of additional
lineages, was achievement of a new steady state with low urease activity. The new
community persisted long term – ASF-transplanted mice showed low fecal ammonia
levels for over one year in a SPF housing facility (data not shown).
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Figure 2-5. Transfer of ASF leads to reduction in urease activity and fecal
ammonia levels. (A) Urease activity in the feces of a conventionally-housed mouse
versus a mouse treated with antibiotics and a mouse colonized with ASF. (B) In vivo
urease activity in conventionally-housed (n=5) and ASF-colonized mice (n=5) quantified
by the release of 13CO2 after IV injection of 13C-urea. (C) Fecal urease activity in
Prepared mice post-ASF transplantation at the indicated time points on irradiated diet
(n=3). (D) Fecal ammonia levels pre- and post-transplant of ASF into Prepared mice fed
a non-irradiated diet (n=5). *p<0.01, **p<0.001. Tukey’s test for multiple comparisons.
The resilience of this new community state to dietary stress was evaluated by
placing mice transplanted with ASF on a low protein diet similar to those used in patients
with hyperammonemic inborn errors of metabolism

34

. Fecal ammonia levels remained

much lower than was achieved by a low protein diet alone, an effect that was durable for
several months (T.D.S. and G.D.W., unpublished observations). Another dietary stress,
consumption of a non-irradiated diet, led to the displacement of ASF by other bacteria
within weeks after FMT, with the predominant taxon Parabacteroides ASF519 being
partially replaced by other taxa within the Bacteroidetes phylum (Supplementary Fig. 2-
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2). Nevertheless, the reduction in fecal ammonia levels compared to baseline remained
significant for several months even on a non-irradiated diet (Fig. 2-5D). Reductions in
fecal ammonia levels have been correlated with reductions in blood ammonia

14, 35, 36

,

indicating that changes in colonic ammonia production and/or absorption can be
associated with blood levels. The reduction in fecal ammonia may alter levels of false
neurotransmitter precursors produced by the gut microbiota and/or by the host since
ammonia is a substrate for both, leading to reduced formation of biogenic amines that
are hypothesized to play a role in hepatic encephalopathy

37-39

. Thus we propose that

fecal ammonia is a useful biomarker for response of the host to the treatment of
hyperammonemia.

ASF transplantation reduced mortality and cognitive impairment in murine models
of acute and chronic liver injury.
A major cause of morbidity and mortality associated with acute liver injury is the
development of HE. Since hyperammonemia is associated with the development of HE
in patients with impaired hepatic function 8, we asked if the transplantation of ASF might
mitigate the effects of acute hepatic injury induced by thioacetamide (TAA)

40

treatment.

Prepared ASF-transplanted (Prepared + ASF) mice showed both a reduction in fecal
ammonia levels (Supplementary Fig. 2-3A) and reduced mortality in response to highdose TAA compared to mice with conventional microbiota (Fig. 2-6A). This finding was
also seen in the setting of chronic liver injury in mice transplanted three weeks prior to
the chronic delivery of TAA at low-escalating doses for 7 weeks (Fig. 2-6B). Compared
to control mice, Prepared + ASF mice demonstrated markedly reduced mortality that
was maintained over the 7-week period during which hepatic fibrosis developed in both
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groups41, 42 (data not shown), consistent with a sustained reduction in fecal ammonia for
months after ASF transplantation.

Figure 2-6. ASF transplantation into Prepared mice reduces mortality after
thioacetamide-induced hepatic injury and fibrosis. (A) Kaplan-Meier survival curves
of high-dose TAA-induced acute hepatic injury in conventional vs. Prepared mice
transplanted with ASF (n=15 per group). (B) Kaplan-Meier survival curves of low
escalating doses of three times weekly chronic TAA administration initiated three weeks
after ASF transplantation (n=15 per group). Survival curves were analyzed by the
Kaplan-Meier method using the log-rank test.
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In mice, the TAA model has also been associated with neurobehavioral
abnormalities resembling HE in humans

43

. Using a lower dose of TAA to reduce

mortality, we analyzed memory and spatial learning in a Y-maze test comparing
Prepared + ASF mice to mice transplanted with normal microbiota (Prepared + Normal
Microbiota) as a control 44. The survival rates were similar between the two groups at 8090% at the lower TAA dose (Supplementary Fig. 2-3B). Fecal ammonia levels were
reduced in mice transplanted with ASF compared to normal microbiota (Supplementary
Fig. 2-3C). Prepared + Normal Microbiota mice showed a decrease in cognitive function
after TAA treatment, quantified as spontaneous alternations in a Y-maze test, whereas
Prepared + ASF mice treated with TAA were not different from untreated controls (Fig.
2-7A). Mice transplanted with ASF and normal microbiota did not differ in locomotor
activity after TAA treatment (as quantified by total distance traveled and number of arm
entries in the Y-maze) to account for the difference in spontaneous alternations,
although both groups exhibited significantly less locomotor activity compared to
untreated controls (Figs. 2-7B and 2-7C). To exclude the possibility that ASF
transplantation

directly

reduced

liver

injury,

we

measured

plasma

alanine

aminotransferase (ALT) and quantified histologic evidence of hepatocyte necrosis
(Supplementary Figs. 2-4A and 2-4B). Both revealed that liver damage induced by
TAA was not reduced by either ASF transplantation or antibiotic treatment. Thus
improved survival and behavioral performance were associated with reduced ammonia
levels and not improved locomotor activity or liver injury.
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Figure 2-7. ASF transplantation into Prepared mice restores cognitive but not
locomotor deficits after thioacetamide-induced hepatic injury. (A) Spontaneous
alternations after TAA treatment quantified by Y-maze testing in Prepared mice that
received transplantation with either Normal Microbiota (n=10) or ASF (n=11), compared
to untreated control mice (n=5) (*p<0.05; ANOVA p=0.04). (B) Total distance traveled
and (C) number of arm entries in the Y-maze in Prepared + ASF and Prepared + Normal
Microbiota mice after TAA treatment compared to untreated control mice (***p<0.001;
ANOVA p<0.001).

2.5 DISCUSSION
The success of FMT in the treatment of C. difficile infection (CDI) establishes that
transplanting a resilient microbial community can alter a dysbiotic microbiota and thereby
treat disease. Feces, however, contains not only bacteria but also a multitude of archaea,
fungi, and viruses, so there is concern for safety
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, motivating development of defined

microbial consortia for human inoculation that have well-characterized biological
properties and respond to the gut environment in predictable ways. Here we show that a
defined minimal consortium of bacteria, ASF

17, 18

, can durably reprogram the

composition and metabolic function of the gut microbiota when inoculated into a properly
prepared host. By taking advantage of the minimal urease activity in ASF, we provide
evidence that reprogramming the gut microbiota can lead to lower fecal ammonia levels
and mitigate the morbidity and mortality associated with liver damage.
The endogenous gut microbiota needed to be depleted by treatment with oral
antibiotics and PEG for efficient transfer of the ASF community into conventionally
housed mice. After the gut purge, transfer was as effective as into germ-free recipients.
Tracking by sequencing suggested an orderly succession of lineages. After ASF
transplantation, the predominant ASF519 strain appeared at the earliest times after
gavage. Mucispirillum schaedleri (ASF457), and Ruminococcaceae (ASF500) also
appeared early on. The last to appear was the Clostridium sp. (ASF356) at day 14 in
some mice, one week after gavaging was complete, perhaps indicating the need for the
development of a specific niche that permitted the establishment of more fastidious taxa.
Most mice contained a Lactobacillus strain indistinguishable from ASF361 prior to
transplantation, so this lineage could not be tracked with the methods used. The
observed succession may be similar to the succession of bacterial taxa in human infants
as consumption of oxygen by initial gut colonizers allows the expansion of bacterial
clades that are obligate anaerobes 46, 47.
By monitoring the composition of the transplanted ASF community over four
months by 16S rRNA gene sequencing, we were able to assess its persistence in the
non-sterile SPF environment. The ASF community did not fully exclude other taxa. The
community appeared to achieve a new steady state whereby both types of transplanted
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hosts came to resemble the mice colonized with ASF from birth housed long-term in a
SPF environment. In each of these three groups, Parabacteroides (ASF519) remained
the dominant taxon. Bacteria of the Bacteroides genus commonly dominate the human
and murine gut microbiota

31, 48-51

, but new Bacteroides did not accumulate over time in

ASF-colonized mice, suggesting that Parabacteroides may have excluded Bacteroides,
reminiscent of the “trade-off” between Bacteroides and Prevotella in human gut

22, 31, 52, 53

The mechanism by which Parabacteroides excludes Bacteroides is unknown but, due to
their taxonomic and functional similarities, may involve competition for limiting resources
54

such as has been shown for glycans and the competition between Bacteroides

species in the colonic crypt

55

. Over time, the Parabacteroides and environmental

Firmicutes established a new steady state approximating the composition of the
conventional microbiota in humans and mice

48, 49, 56

possibly involving a syntrophic

relationship between these lineages 57.
There was a sustained reduction in fecal urease enzymatic activity and ammonia
production upon transfer of ASF into Prepared mice. There was no return of urease
activity several months after transfer despite a substantial increase of non-ASF taxa.
Possible lack of urease genes in many of the Clostridium taxa that accumulated after
transplantation may explain the persistently reduced urease activity, although we cannot
exclude other mechanisms since the regulation of urease enzymatic activity is known to
be complex 6.
Production of ammonia by the gut microbiota has been implicated in host
nitrogen balance

58-60

, so there is a theoretical risk that a urease-free community might

have an adverse effect on protein balance and growth of the host. However, we have
tracked mice for over 1 year post-ASF transplantation and have not observed any
adverse effects on body weight or mortality. ASF is acknowledged to be an innocuous
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.

bacterial consortium in mice with beneficial effects on immune tolerance 18. Nevertheless,
additional safety studies will need to be performed using a humanized version of ASF in
rodent models before human studies can be contemplated.
In summary, given that HE is a major contributor to morbidity and mortality in
liver disease

61

, transplantation of next-generation engineered communities based on

ASF, coupled with improved preparation of the host as described here, represents a
promising approach to more effective therapy.
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2.8 SUPPLEMENTARY INFORMATION

Supplementary Figure 2-1. Distinctiveness and long-term resiliency of the Altered
Schaedler’s Flora (ASF) in a host housed in a conventional specific pathogen free
(SPF) environment. (A) 16S rRNA gene copy number of conventional (n=5) vs. ASF
(n=10) fecal microbiota (p=0.015). (B) PCoA ordination of conventional (n=5) vs. ASF
(n=10) communities based on 16S rRNA gene sequence tags. (C) Relative abundance
of individual ASF community members in mice (n=10) housed in a SPF environment
over 2 months. Two-tailed Student’s t-test.
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Supplementary Figure 2-2. Effect of a non-irradiated normal chow diet on ASF
resilience after transplantation. Heat map showing the relative abundance of bacterial
lineages over time in ASF-transplanted mice (n=5). Rows indicate bacterial lineages as
annotated on the left. Relative abundance is indicated by the color code at the top of the
figure, columns summarize sequencing results from individual fecal specimens, and
elapsed time in days is shown along the bottom.
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Supplementary Figure 2-3. Fecal ammonia levels, mortality rates and histology
associated with TAA-induced hepatic injury studies. (A) Post-ASF transplant fecal
ammonia levels in the high-dose TAA study shown in Figure 6A. (B) Kaplan-Meier
survival curves and (C) fecal ammonia levels in the low-dose TAA study associated with
results shown in Figure 7. (D) Photomicrographs of H&E stained hepatic sections from
mice treated with high-dose TAA as indicated (200X) with quantification of hepatocellular
necrosis (Supplementary Figure 4B). *p<0.01, ***p<0.001. Two-tailed Student’s t-test
and paired-sample t-test.
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Supplementary Figure 2-4. Differential liver injury do not explain differences with
or without ASF transplantation. (A) Plasma alanine aminotransferase (ALT) levels in
control, antibiotic-treated, or ASF-transplanted mice after TAA treatment compared to
untreated control mice (n=3 in untreated control group, n=7 in control + TAA group, n=4
in ABX +TAA group, n=8 in ASF + TAA group). (B) Liver damage quantified
histologically by a pathologist reported as percent hepatic cellular necrosis (n=5 each in
untreated control group and ABX + TAA group, n=10 each in control + TAA group and
ASF + TAA group; 10 random 200x HPF per liver, no statistically significant difference
among the three TAA-treated groups by ANOVA; blinded analysis).
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CHAPTER 3. Dietary Regulation of the Gut Microbiota Engineered by a
Minimal Defined Bacterial Consortium

The contents of this chapter have been submitted as:
Shen TC, Chehoud C, Ni J, Hsu E, Chen YY, Bailey A, Laughlin A, Bittinger K,
Bushman FD, Wu GD. Dietary regulation of the gut microbiota engineered by a
minimal defined bacterial consortium. PLOS ONE 2016 (under review).

Personal contribution:
1) Assistance with overall study design
2) Experiment implementation, sample collection, and data analyses and
interpretation of all murine studies in terms of metabolic phenotyping, dietary
interventions, and fecal microbiota transplantation (excluding 16S rRNA gene
sequencing and analyses)
3) Biochemical assessments of fecal/serum urea and fecal ammonia levels in all
related experiments
4) Assistance with drafting and revising the relevant sections of the manuscript
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3.1 ABSTRACT
We have recently reported that Altered Schaedler Flora (ASF) can be used to
durably engineer the gut microbiota to reduce ammonia production as an effective
modality to reduce morbidity and mortality in the setting of liver injury. Here we
investigated the effects of a low protein diet on ASF colonization and its ability to
engineer the microbiota. Initially, ASF inoculation was similar between mice fed a normal
protein diet or low protein diet, but the outgrowth of gut microbiota differed over the
ensuing month. Notable was the inability of the dominant Parabacteroides ASF taxon to
exclude other taxa belonging to the Bacteroidetes phylum in the setting of a low protein
diet. Instead, a poorly classified yet highly represented Bacteroidetes family, S24-7,
returned within 4 weeks of inoculation in mice fed a low protein diet, demonstrating a
reduction in ASF resilience in response to dietary stress. Nevertheless, fecal ammonia
levels remained significantly lower than those observed in mice on the same low protein
diet that received a transplant of normal feces. No deleterious effects were observed in
host physiology due to ASF inoculation into mice on a low protein diet. In total, these
results demonstrate that low protein diet can have a pronounced effect on engineering
the gut microbiota but modulation of ammonia is preserved.

3.2 INTRODUCTION
The gut microbiota responds to multiple environmental stressors such as diet

1-4

,

antibiotic use 5, inflammation of the intestinal tract 6, and infection of the host with enteric
pathogens 7. By studying the gut microbiota in pediatric patients with Crohn’s disease,
we have recently shown that the effects of these factors may be independent even if
present simultaneously 8. Amongst these, the impact of diet has received considerable
attention as a potential modifiable factor that shapes the composition and/or function of
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the gut microbiota to prevent and/or treat disease 9. The high-level efficacy of fecal
microbiota transplantation (FMT) in the treatment of Clostridium difficile infections (CDI)
is proof of concept that inoculating a host with a consortium of microbes has a
meaningful effect on the composition of the gut microbiota

10

considered an untargeted approach with potential risks

. The use of feces could be
11

, but growing evidence

suggests that the use of defined microbial consortia could be developed to treat disease
12, 13

. We have recently shown that the gut microbiota can be durably reconfigured to

reduce fecal urease activity and ammonia production through oral inoculation of Altered
Schaedler Flora (ASF), a defined microbial consortium that contains minimal urease
gene content

13

. ASF comprises 8 murine gut commensal bacterial strains assembled in

the 1970s and standardized by the National Cancer Institute in 1978

14

. It is now

commonly used to create gnotobiotic mice and/or to enhance the health of
immunodeficient mouse strains.
Examples of co-metabolism between the gut microbiota and its mammalian host
requiring host-derived substances include bile acids, mucous, and urea. The latter is
particularly important for nitrogen flux between the host and the gut microbiota

15, 16

. As

the primary source of nitrogen, dietary protein is essential to the synthesis of nucleic
acids, amino acids, and other nitrogenous compounds. The catabolism of dietary protein
by the host leads to hepatic formation of urea, a nitrogenous waste product that is
excreted through the urine or delivered into the colon, where hydrolysis by bacterial
urease results in the production of carbon dioxide and ammonia. Ammonia is a shared
substrate for the synthesis of proteins, amino acids, and other small molecules by both
the host and its microbiota. Although generally thought to be nutritionally beneficial to the
host by enhancing nitrogen recycling, the production of ammonia by the gut microbiota
can have deleterious effects in the setting of altered hepatic function, resulting in the
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development of neurotoxicity

17-19

. Under such conditions, a low protein diet (LPD) can

be used to reduce systemic ammonia levels 20, 21.
By inoculating mice with ASF after the endogenous microbiota has been reduced
through the use of antibiotics and polyethylene glycol (PEG), the composition of the gut
microbiota can be durably modified in composition as well as function. Functionally,
there was a long-lasting reduction in fecal ammonia that was effective in reducing
morbidity and mortality in the thioacetamide model of liver injury

13

. Since (1) the

absorption of fecal ammonia produced by the gut microbiota may be an important source
of nitrogen for the host especially in the setting of dietary protein restriction

15

, and (2)

low protein diets are used clinically in patients with hyperammonemic inborn errors of
metabolism

22

, there are a number of questions about the impact of diet on the

engineering of the gut microbiota to reduce ammonia production. What is the effect of a
LPD on the ability of a defined bacterial consortium to colonize in the gut? Does a LPD
have an effect on the composition of the engineered microbiota? Will the ammonia
reduction by microbiota engineering be sustained and exhibit lower levels than those
achievable by a LPD alone? And lastly, will a significant reduction in gut microbiota
ammonia production be deleterious to the host on a LPD?
Here, we address these questions by inoculating mice on a LPD with either feces
from conventionally-reared mice (Normal Feces, or NF) or with ASF, monitoring the
resultant composition of the gut microbiota over time by 16S tagged sequencing,
assessing functionality by quantifying fecal ammonia levels, and investigating the impact
on the host by metabolic profiling. Although a LPD has no effect on the ability of ASF to
colonize the gut of the host upon inoculation, the resultant engineered state of the
microbiota is altered primarily due to the re-emergence of S24-7, a specific bacterial
taxonomic family within the Bacteroidetes phylum. Despite this alteration, fecal ammonia
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levels remain diminished and without consequence to the metabolic physiology of the
host on a LPD.

3.3 MATERIALS AND METHODS
Animals
C57B6J female mice 8 to 12 weeks old (The Jackson Laboratory) were used in this
study. Fecal pellets collected from five ASF-colonized CB17 SCID mice (Taconic) served
as the source of the ASF inoculum whereas five conventionally-colonized C57B6J mice
(The Jackson Laboratory) served as the source of the normal feces (NF) inoculum used
in the FMT procedures as previously described

13

. Fecal homogenates were prepared by

diluting 0.1 g feces 10-fold in PBS. Mice were prepared for FMT by oral delivery of
antibiotics in drinking water (1.125 g aspartame, 0.15 g vancomycin, and 0.3 g neomycin
in 300 mL sterile water) for 72 hours. During the final 12 hours, the water supply was
exchanged with a 10% PEG solution (Merck), and the mice were fasted. Mice were then
inoculated daily with fecal homogenates by oral gavage for 7 days. All mice were housed
five per cage in a conventional specific-pathogen free (SPF) facility (and transferred from
one conventional facility to another conventional facility within the University of
Pennsylvania 10 weeks after the start of experiment for NMR imaging) and fed irradiated
AIN-76A (Research Diets D10001, 21% protein by kilocalories – NPD, see S1 Table).
After one week, ten mice were switched to irradiated AIN-76A with lower protein content
(Research Diets D08092201, 3% protein by kilocalories – LPD, see S1 Table). Fecal
pellets were collected at baseline on NPD, 10 weeks after placement on LPD, 2 weeks
after FMT (15 weeks on LPD), 4 weeks after FMT (17 weeks on LPD), and 10 weeks
after FMT (23 weeks on LPD) for bacterial taxonomic and biochemical analyses. Fecal
pellets were collected in 1.5 mL microcentrifuge tubes (Sigma-Aldrich) and immediately
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placed on dry ice then stored in -80°C freezer until time of analysis. Body composition
was determined after ten weeks on respective diets using NMR imaging via the Mouse
Phenotyping, Physiology and Metabolism Core at the University of Pennsylvania. All
animal studies were performed with the approval of the Institutional Animal Care and
Use Committee of the University of Pennsylvania (Protocol Number: 803408).

16S V1-V2 Sequencing
DNA was isolated from stool as previously described

2, 23

. 100 ng of DNA was amplified

with barcoded primers annealing to the V1-V2 region of the 16S rRNA gene (forward
primer, 5′-AGAGTTTGATCCTGGCTCAG-3′; reverse primer, 5′-CTGCTGCCTYCCGTA3′;

24, 25

using AccuPrime Taq DNA Polymerase System with Buffer 2 (Life Technologies).

PCR reactions were performed on a thermocycler using the following conditions:
initiation at 95°C for 5 min followed by 20 cycles of 95°C × 30 s, 56°C × 30 s, and 72°C ×
1 min 30 s, then a final extension step at 72°C for 8 min. The amplicons from each DNA
sample, which was amplified in quadruplicate, were pooled and purified with Agencourt
AMPure XP beads (Beckman Coulter) following the manufacturer’s instructions. Purified
DNA samples were then sequenced using the 454/Roche GS FLX Titanium chemistry
(454 Life Sciences).

16S rRNA Gene Sequence Analysis
16S rRNA gene sequence data was processed with QIIME v 1.8.0

26

using default

parameters. Sequences were clustered into operational taxonomic units (OTUs) at 97%
similarity and then assigned Greengenes taxonomy

27

using the uclust consensus

taxonomy classifier. Sequences were aligned using PyNAST
was constructed using FastTree
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and a phylogenetic tree

. Weighted and unweighted UniFrac
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distances were

calculated for each pair of samples for assessment of community similarity and
generation of principal coordinate analysis (PCoA) plots.

Statistical analyses for

bacterial abundance difference was performed using non-parametric Wilcoxon test, and
p-values were corrected for multiple comparisons using the Benjamini and Hochberg
procedure.

Measurement of fecal ammonia
Fecal ammonia concentrations were determined using an Ammonia Assay Kit (ab83360,
Abcam, Cambridge, MA). Fecal pellets were suspended in the assay buffer provided at a
concentration of 1 mg/10 uL, homogenized, and centrifuged at 13,000 x g for 10 minutes
at room temperature to remove insoluble material. Ammonia concentration was then
determined according to the kit protocol.

Measurement of serum and fecal urea
Urea concentrations were determined using the QuantiChrom™ Urea Assay Kit (DIUR500, Bioassay Systems, Hayward, CA). Serum samples were assayed directly. Fecal
pellets were suspended in ddH2O at a concentration of 1 mg/10uL, homogenized, and
centrifuged at 2,500 x g for 10 minutes at room temperature to remove insoluble material.
Urea concentration was then determined according to the kit protocol.

3.4 RESULTS
LPD impacts host physiology and nitrogen metabolism but modestly alters the
composition of the gut microbiota.
We first set out to investigate the effects of a LPD on both the murine host and
the gut microbiota. Fifteen adult female C57BL6J mice were placed on an open source
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irradiated purified rodent diet containing normal amount of dietary protein at 21% by
kilocalories

(AIN-76A),

henceforth

referred

to

as

normal

protein

diet

(NPD,

Supplementary Table 3-1) for one week upon arrival into the University of Pennsylvania
SPF vivarium. Subsequently, ten of the 15 mice were switched to an irradiated low
protein diet (LPD, Supplementary Table 3-1) formulated using AIN-76A as the base
that contains 3% protein by kilocalories. The LPD was made isocaloric by proportionally
increasing carbohydrate content while keeping fat content unchanged. The remaining 5
mice continued to be fed the NPD. We monitored physiological changes in these mice
using body weight and food intake measurements as well as body composition
determination via nuclear magnetic resonance (NMR) imaging. We found that compared
to NPD-fed mice, LPD-fed mice exhibited poor weight gain despite equivalent caloric
consumption (Fig. 3-1A). LPD-fed mice also demonstrated increased fat mass and
decreased lean mass (Fig. 3-1B and 3-1C). Corresponding to a reduction in serum urea
concentration compared to NPD-fed mice (Fig. 3-1D), LPD-fed mice exhibited significant
reductions in fecal urea and fecal ammonia levels after ten weeks on the LPD (Fig. 3-1E
and 3-1F). These results are consistent with the fundamental role that dietary protein
plays in host nitrogen balance. Reduction in dietary protein may have an effect on the
gut microbiota by reducing the delivery of urea to the colonic environment leading to the
reduction in fecal ammonia levels.
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Figure 3-1. Changes in murine physiology and nitrogen metabolism on a LPD.
Differences in (A) body weight (n=5 in NPD group, n=10 in LPD group), (B) % fat mass,
(C) % lean mass, and (D) serum urea concentrations between NPD-fed and LPD-fed
mice. (E) Fecal urea and (F) fecal ammonia levels at baseline on the NPD and after
placement on the LPD. Values represent mean ± SEM. Statistical significance in body
weight determined by two-way ANOVA with repeated measures; statistical significance
in other parameters determined by paired and unpaired two-tailed Student’s t test.
*p<0.05, **p<0.01, ***p<0.001.
16S tagged sequencing (1045 to 5305 reads per sample, median = 3448 reads)
revealed modest yet distinct differences in the composition of the fecal microbiota in
mice after placement on the LPD. These difference can be visualized in principal
coordinates analysis of weighted (Fig. 3-2A) and unweighted (Fig. 3-2B) UniFrac
distance. The LPD led to a significant increase in the diversity of the gut microbial
community as assessed by the Shannon diversity index (Fig. 3-2C and Supplementary
Fig. 3-1). The LPD also led to significant increases in the relative abundance of
Mollicutes and Coriobacteria and a decrease in the Firmicutes classes Erysipelotrichi
and Clostridia (Fig. 3-2D and 3-2E).
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Figure 3-2. Effect of a LPD on the composition of the gut microbiota. Principal
coordinates analysis (PCoA) ordination of mice before and after placement on the LPD
for 10 weeks. Changes in community membership were analyzed using (A) weighted
and (B) unweighted Unifrac. (C) The interquartile range of Shannon diversity values is
shown for mice on the NPD who were later put on the LPD (Wilcoxon rank sum test pvalue = 0.0001299). (D) Heatmap showing the relative abundance of bacterial lineages
over time in mice who were on the NPD at baseline and then after ten weeks on the LPD.
Rows indicate bacterial lineages annotated at the class taxonomic level on the left. The
color key on the right of the figure indicates relative abundance. Columns summarize the
sequencing results from individual fecal specimens. Each column represents a different
mouse. The columns are grouped by diet. (E) Bacterial lineages that change on the LPD.
Four bacterial classes significantly differed between the NPD and LPD (FDR-corrected
Wilcoxon test p-value < 0.05). Relative abundance of each class in both diet groups is
shown. Box and whiskers show the interquartile range; black circles mark the outlier
samples.

LPD has no effect on the initial colonization of ASF into the host microbiota.
We have previously shown that there is a reduction in gut bacterial biomass upon
treatment of mice with oral antibiotics (vancomycin and neomycin) and PEG, thus
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permitting the colonization of ASF upon inoculation by oral gavage

13

. However, the

effect of a LPD on the colonization of ASF into the gut of a prepared host remains
unknown. After preparation with antibiotics and PEG, we orally inoculated five of the
LPD-fed mice with ASF (herein referred to as “ASF-transplanted”). As a control group,
we transplanted the other five LPD-fed mice using feces from conventionally-reared
donor mice (herein referred to “NF-transplanted,” for Normal Feces). Using 16S rRNA
tagged sequencing, we tracked taxonomic alterations in the gut microbiota over time.
We found that NF-transplanted mice exhibited minimal change in the composition of
their gut microbiota (Supplementary Fig. 3-2). However, the gut microbiota of ASFtransplanted mice underwent a shift in composition in a similar fashion to that previously
observed in NPD-fed mice transplanted with ASF 13, as shown in Fig. 3-3A and 3-3B. In
particular, the shifts along PC1 in both cohorts of mice represent changes due to the
initial ASF inoculum (compare days 0 to 14 in both groups), whereas differences
between the two cohorts of mice along PC2 may represent the effect of diet. These
findings suggest that a LPD does not affect the initial colonization of ASF into the host
microbiota.
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Figure 3-3. Effect of a LPD on the initial colonization of ASF and subsequent
resilience over time. Principal coordinates analysis (PCoA) ordination of mice after
transplantation with ASF. Changes in community membership were analyzed using (A)
weighted and (B) unweighted Unifrac. Dietary groups are color coded as indicated with
the shades of colors indicating progression in time. Day 0 samples have gray circles
around them (solid for NPD, dashed for LPD). The arrows were added to help visualize
the progression of time after ASF transplantation. (C) The interquartile range of Shannon
diversity values are shown for mice on the NPD and LPD inoculated with either ASF or
Normal Feces (NF). Black circles mark the outlier samples.

Diet affects the resilience of the gut microbiota engineered by inoculation with
ASF.
By tracking the composition of mice inoculated with ASF, we determined the
effect of a LPD on the ability of ASF to engineer a different microbiota composition. In
the setting of a NPD, we previously observed that ASF transplantation led to the
development of a new steady state community after one month composed of both ASF
and the return of selected taxa of the Firmicutes phylum, but no non-ASF Bacteroidetes
13

	
  

. We proposed that Parabacteroides ASF519, the dominant taxon in ASF in feces, may
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have prevented the return of other Bacteroidetes taxa by competitive niche exclusion.
Tracking compositional changes in the gut microbiota over time, we found that in the
setting of the LPD, the gut microbiota engineered by ASF inoculation developed into an
alternative rich community with diversity similar to that on the NPD (Fig. 3-3C). However,
ASF519 did not suppress the return of other Bacteroidetes. Instead, Bacteroidetes S247, a poorly classified yet common bacterial taxon in the commensal murine gut
microbiota

31, 32

, returned after ASF transplantation and reached an equilibrium state with

ASF519 (Fig. 3-4 and Supplementary Fig. 3-3). We plotted the progression of the
transplanted ASF community over time. We found that ASF reached a new steady state
in the setting of the LPD at around 4 weeks after transplantation, similar to what we
previously observed in the setting of the NPD

13

(Fig. 3-3A and 3-3B). However, this

steady state more closely resembled the endogenous microbiota, likely as a result of the
return of S24-7 on the LPD (best observed in Fig. 3-3A along PC1 – compare the solid
to dotted grey line). Overall, these findings suggest that ability of ASF lineages to
compete is reduced in the presence of a LPD.
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Figure 3-4. S24-7 returns after ASF transplantation into mice on a LPD but not on a
NPD. (A) Relative abundance of bacterial taxa are shown. Each column represents a
single sample of a pre-treated, ASF-inoculated mice on the LPD (LPD + ASF).
Progression of inoculation is shown across multiple days post inoculation with ASF.
Relative abundance of (B) Parabacteroides (including ASF 519) and (C) S24-7. Box and
whiskers show the interquartile range; black circles mark the outlier samples.

The ASF-engineered gut microbiota lowers fecal ammonia more effectively than
LPD alone.
We have previously shown that ASF transplantation durably reduces fecal
ammonia by decreasing fecal urease activity

13

. Since a LPD itself mainly reduces fecal

ammonia by decreasing the delivery of urea to the colon (Fig. 3-1E and 3-1F), we
sought to determine whether the ASF-engineered microbiota would be able to reduce
fecal ammonia levels below those achieved by a LPD alone. We measured fecal urea
and fecal ammonia in mice at baseline on the NPD, after ten weeks on the LPD, and
compared ASF and NF transplantation on the LPD. As shown in Fig. 3-5A, after the
initial reduction in fecal ammonia levels induced by the LPD, ASF transplantation
reduced fecal ammonia further than did NF transplantation. The ability of the ASF-
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engineered microbiota to lower fecal ammonia levels below those achieved by the LPD
alone is likely due to the reduction in fecal urease activity since there was no difference
in fecal urea levels after NF and ASF transplantation (Fig. 3-5B). These results indicate
that the functionality of the ASF-engineered gut microbiota is not significantly altered in
the setting of a LPD despite alterations in its composition.
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Figure 3-5. ASF transplantation alters colonic urea nitrogen recycling without
significantly affecting host physiology. (A) ASF transplantation reduces fecal
ammonia below the level achieved by the LPD alone (n=4-5 per group, *p<0.05
compared to baseline, **p<0.01 compared to 10 weeks on the LPD). (B) No difference in
fecal urea level between ASF- and NF-transplanted mice (n=2-5 per group, *p<0.05
compared to baseline, **p<0.01 compared to baseline). No difference in (C) body weight
or (D) food intake between ASF- and NF-transplanted mice (n=5 per group). Values
represent mean ± SEM. Significance determined by two-tailed Student’s t-test.
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The low fecal urease and fecal ammonia-producing microbiota engineered by ASF
inoculation does not exacerbate host metabolic dysfunction induced by LPD.
Urea is a nitrogenous waste product, but it is thought to contribute to host
nutrition via urea nitrogen recycling by intestinal bacterial urease in both ruminants and
non-ruminants, leading to microbial and/or host synthesis of peptides, amino acids, and
other small molecules

15

. We asked whether this role of urea may become important for

host physiology in the setting of a LPD, where systemic nitrogen is reduced. After
transplanting the above cohort of mice with ASF or NF, we continued to monitor their
body weight, food intake, and survival. Remarkably, despite the absence of colonic urea
nitrogen recycling, ASF-transplanted mice did not differ significantly from NFtransplanted mice (Fig. 3-5C, 3-5D, and Supplementary Fig. 3-4). Thus, in the setting
of a LPD, ASF transplantation does not lead to significant detrimental changes to host
physiology and metabolism.

3.5 DISCUSSION
The success of FMT in the treatment of recurrent Clostridium difficile infections
provides proof of concept that the gut microbiota can be a target for the treatment of
disease in humans. The use of fecal transfer will likely be replaced by the use of defined
microbial consortia with specific biological properties. As proof of concept, we have
shown in murine models that a defined consortium of eight bacteria, known as Altered
Schaedler Flora (ASF), can be used to engineer the gut microbiota with altered
functionality, namely a reduction in fecal urease activity and ammonia production

13

.

Critical to the success of this strategy is the substantial reduction in the biomass of the
baseline microbiota to provide a niche into which the bacterial inoculum can colonize.
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An important consideration for engineering the gut microbiota is resilience to
environmental stress. An optimally engineered microbiota would be a rich community
that stays intact in the presence of environmental stress. Diet is an important
environmental stressor on the gut microbiota that should be considered when
engineering gut microbial communities. As one example, the low ammonia-producing
microbiota engineered by ASF, which has functional durability for several months in mice
fed an irradiated diet, shows reduced resilience when the mice are fed a non-irradiated
diet

13

. We chose to study the impact of dietary protein on the resilience of the ASF-

engineered microbiota for several reasons: 1) Dietary protein has been shown to
influence the composition of the gut microbiota in gnotobiotic mice

33

; 2) Protein

consumption regulates the production of hepatic urea that may affect colonic urea
delivery to the gut microbiota

15, 34

; 3) Protein-restricted diets are an important

therapeutic modality for patients with hyperammonemic inborn errors of metabolism 21, 35.
Unlike the modulation of fat and fiber in mice, which have been shown to have a
strong effect on the composition of the murine gut microbiota

1, 33

, we show that severe

restriction of dietary protein had a modest effect. Within the Firmicutes phylum the
Clostridia and Erysipelotrichi classes decreased significantly on a LPD, consistent with
the preference of taxa within Firmicutes, particularly Clostridia species, to metabolize
amino acids and peptides

36, 37

. Alternatively, since we show that a LPD reduces serum

urea concentrations with reduced delivery to the colon resulting in lower fecal ammonia
levels, an alteration in nitrogen flux via ammonia into the gut microbiota

38, 39

may also

have an effect on the composition of the bacterial microbiota.
Since we balanced protein with carbohydrate in the composition of the purified
rodent diets, it is difficult to ascertain if the differences in the composition of the gut
microbiota are due primarily to alterations in protein or in carbohydrate. We found that
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two bacterial phyla present at low abundances increased significantly on a LPD.
Specifically,

the

classes

Mollicutes

(Tenericutes

phylum)

and

Coriobacteria

(Actinobacteria phylum) increased on a LPD. Previous work has shown that Mollicutes
proliferated on a typical Western diet characterized by high-fat/high-sugar content, likely
because of their ability to import and process simple sugars

40

. Thus, an increase in the

abundance of Mollicutes that we observed on a LPD could be due to the increase in
carbohydrate content rather than the reduction in protein content. Another study also
showed that gut colonization by Actinobacteria and Tenericutes was strongly correlated
with decreased hepatic levels of glycogen and glucose

41

, further suggesting the

interplay between the host and these two phyla may be closely related to carbohydrate
metabolism.
Despite the effect of a LPD on the composition of the murine gut microbiota at
baseline, this did not have an effect on the initial colonization of ASF at 2 weeks,
demonstrating that the use of antibiotics and PEG effectively prepared the environment
of the gut for inoculation by a minimal defined bacterial consortium. Subsequently,
development of the resultant engineered microbiota, determined by emergence of
various bacterial taxa in addition to ASF, was distinctly different in mice fed a NPD
versus a LPD. On a NPD, we previously showed that the dominant taxon
Parabacteroides (ASF519) was able to exclude the entire Bacteroidetes phylum yet
permit the reappearance of specific taxa belonging to the Firmicutes phylum. The
observation that bacterial lineages with similar phylogeny exhibit competitive niche
exclusion has been demonstrated in the Bacteroides genus where successful
competition for carbohydrate substrates plays an important role 42. By contrast, on a LPD,
the resultant engineered microbiota appears to be more similar to baseline primarily due
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to the reemergence of a single bacterial taxon belonging to the Bacteroidetes family,
S24-7.
S24-7 has been previously recognized as a dominant taxonomic group in the
murine microbiota. It was first characterized by Salzman et al., who referred to the taxon
as “mouse intestinal bacteria”

31

. The S24-7 taxon is phylogenetically distinct from other

named genera in the order Bacteroidales. The taxon has been reported as altered in
several recent mouse studies: it was increased in proportion following partial
hepatectomy

43

, associated with co-infection by Hymenolepis spp.

44

, and decreased in

proportion following antibiotic treatment for parenteral nutrition-associated liver injury

45

.

However, to our knowledge, no study has previously characterized competition between
S24-7 and other Bacteroidetes species in mice. The S24-7 taxon is typically
encountered at very low (<1%) abundance in fecal samples from human populations.
However, one study of a previously uncontacted Amerindian population reported the
taxon to be enriched in isolated Yanomami Amerindians relative to Guahibo Amerindian,
Malawian, and U.S. subjects

46

. The average abundance of the taxon in Yanomami

Amerindians was reported to be nearly 5% of total bacteria, suggesting a potential role
for S24-7 in the human gut.
Upon reduction of bacterial biomass through a combination of antibiotics and
PEG, S24-7 is no longer detectable and shows no return over time after mice have been
inoculated with ASF. Since both Paracteroides (ASF519) and S24-7 are closely related
within the Bacteroidetes phylum, we speculate that S24-7 may be co-excluded from the
luminal gut environment by ASF519 through competitive niche exclusion, a mechanism
that has been hypothesized as the basis for the inversely-related proportions of
Bacteroides and Prevotella in the human gut microbiota

2, 47

, a predominant feature of

“enterotypes” 48. From a mechanistic standpoint, the basis of competitive niche exclusion
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may involve the competition of metabolic substrates as has been demonstrated for
Bacteroides species in a reductionist model system

42

. Since S24-7 reappears and co-

exists at approximately equal levels with ASF519 in LPD-fed mice, the alteration of
substrate availability via diet may have altered the luminal environment of the gut that
reduces the need for competition between these two taxa. For example, a LPD may
have altered the balance of nitrogen flux into the gut microbiota via the uptake of
ammonia. Indeed, despite the return of S24-7 and the similarities between the
composition of a gut microbiota of a conventionally-housed mouse and the ASFengineered community established in LPD-fed mice, fecal ammonia levels remained
much lower in ASF-transplanted mice that those transplanted with normal feces. This
suggests that S24-7 may be urease negative. Further elucidation of such mechanism(s)
will require genomic characterization of S24-7 along with an evaluation of its biological
properties.
The quantification of fecal ammonia was used to determine the impact of
microbiota composition on the function of the community. Despite the modest alterations
in the gut microbiota induced by the consumption of a LPD, there was a significant
reduction in fecal ammonia levels reflecting the reduced abundance of urea substrate
available for hydrolysis by the gut microbiota. This observation emphasizes the notion
that diet may have an indirect impact on the gut microbiota by alteration of the host
similar to the outgrowth of a pathobiont due to the enhanced production of sulfated bile
acids in mice fed milk fat

49

. Importantly, engineering of the gut microbiota using ASF led

to a reduction in fecal ammonia levels significantly greater than that observed on a LPD.
Since ammonia, produced by the gut microbiota via urease activity, is absorbed
by the host where it can be used for amino acid synthesis, it has been hypothesized that
this form of nitrogen recycling may be important for host health especially under
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conditions of limited protein intake 15, 50. This might be a significant limitation of a strategy
focused on reducing gut microbiota ammonia production for the treatment of
hyperammonemia and hepatic encephalopathy

13

. Although LPD-fed mice did not exhibit

growth, as would be expected, ASF transplantation with subsequent robust reduction of
fecal ammonia levels did not lead to any effects on food intake, growth, or mortality
relative to LPD-fed mice transplanted with normal feces who had much higher levels of
fecal ammonia. Since patients with hyperammonemic inborn errors of metabolism are
placed on a LPD to prevent metabolic crises, our observations provide preliminary
evidence that the engineering of gut microbiota to reduce fecal ammonia production may
be well tolerated in this patient population. However, additional safety studies are
needed.
In summary, we show that diet has a significant effect on the ability of a defined
microbial consortium to engineer the composition of the gut microbiota. Specifically, LPD
alters the co-exclusion of two dominant taxa within the Bacteroidetes phylum. Given the
alterations in the syntropic host-microbiota interactions in nitrogen flux that occur in the
levels of urea delivery from the host to the gut microbiota, the reduced production of
ammonia via bacterial urease, and the uptake of ammonia by both the host and the gut
microbiota, a LPD may be a particularly important environmental stressor that will impact
upon the composition of an engineered microbiota. Nevertheless, the functionality of the
engineered gut microbiota, as quantified by a reduction in fecal ammonia levels,
remained intact. Together with the absence of detrimental effects on host physiology in
the setting of a LPD, the reduction in fecal ammonia levels via engineering of the gut
microbiota may be an effective therapeutic strategy for patients with hyperammonemic
inborn errors of metabolism.
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3.8 SUPPLEMENTARY INFORMATION

Supplementary Table 3-1. Components of normal protein and low protein diets.

Shannon Diversity

4

3
Baseline on NPD

2

10 weeks on LPD

1

Mouse 10

Mouse 10

Mouse 9

Mouse 9

Mouse 8

Mouse 8

Mouse 7

Mouse 7

Mouse 6

Mouse 6

Mouse 5

Mouse 5

Mouse 4

Mouse 4

Mouse 3

Mouse 3

Mouse 2

Mouse 2

Mouse 1

Mouse 1

0

Supplementary Figure 3-1. Diversity in each mouse after a LPD. Shannon diversity
is shown for all ten mice while on the NPD (blue) and after ten weeks on the LPD
(salmon).
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Weighted Unifrac Ordination

Unweighted Unifrac Ordination

PC2 (12.1%)

PC2 (12.2%)
LPD Day 0
LPD + ASF Day 14
LPD + ASF Day 30
LPD + ASF Day 75
LPD + NF Day 14
LPD + NF Day 30
LPD + NF Day 75

PC1 (58.1%)

PC1 (35.1%)

Supplementary Figure 3-2. Principal coordinates analysis ordination of mice on
the LPD after transplantation with ASF or NF. Changes in community membership
were analyzed using (A) weighted and (B) unweighted Unifrac.

Supplementary Figure 3-3. Relative abundance of bacterial taxa after ASF
transplantation. Each bar represents a single sample. Samples represent pre-treated
ASF-inoculated mice on the NPD (NPD + ASF). Progression is shown across multiple
days post-inoculation with ASF.
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Supplementary Figure 3-4. Murine mortality on a LPD. Kaplan Meier curve showing
no significant difference in survival between ASF- and NF-transplanted mice on the LPD
(n=5 per group at start of experiment).
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CHAPTER 4. Conclusions and Future Directions

We can dramatically reduce the endogenous biomass of the murine gut through
the use of antibiotics and polyethylene glycol and subsequently reconfigure the
composition and function of the gut microbiota by transplanting a new defined bacterial
consortium. In this dissertation, we reduced gut urea nitrogen recycling and colonic
ammonia production via transplantation of ASF, a defined bacterial consortium with
minimal urease gene content and activity. ASF transplantation was associated with
decreased morbidity and mortality in a murine model of hepatic injury and fibrosis
(Chapter 2). Given the impact of diet on the gut microbiota as well as the use of dietary
protein restriction in the treatment of urea cycle disorders, we also investigated the
effects of a low protein diet (LPD) on the structure and function of the transplanted ASF
community. Although ASF demonstrated decreased resilience in response to dietary
stress on a LPD and allowed the colonization and proliferation of the Bacteroidetes
family S24-7, the ASF-engineered microbial community maintained low colonic ammonia
production (Chapter 3). These findings point to the therapeutic potential of a humanized
ASF for treating conditions of hyperammonemia, such as HE in cirrhosis and urea cycle
disorders. Furthermore, this work provides proof of concept for the therapeutic
modulation of host metabolic processes and informs future investigations into the
management of disease processes through the transplantation of engineered gut
microbiota with targeted physiologic properties.
A number of important questions and challenges remain. Gut ammonia
production and subsequent absorption by the host are strongly implicated in the
pathogenesis of HE. Urea hydrolysis to carbon dioxide and ammonia via bacterial
urease activity in the gut represents a simple metabolic pathway for therapeutic
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intervention. As such, we were able to use a defined bacterial consortium without urease
activity to alter mammalian host nitrogen metabolism and ameliorate the clinical
sequelae of hyperammonemia. However, in disease states with multifactorial and/or
obscure pathogeneses, such as inflammatory bowel disease and obesity, the
identification of pathologic pathways involving the gut microbiota remains unclear. This
lack of clarity makes it difficult to design defined bacterial consortia capable of
modulating these processes. Hippocrates famously said that “all disease begins in the
gut.” While he may not have been insinuating the role of the gut microbiota, the ongoing
challenge is to elucidate the gut microbiota-dependent pathways linked to disease
processes and modulate them to treat or even cure disease. Metabolomic studies may
provide a viable approach. In one example, untargeted metabolomics studies were used
to generate profiles of plasma small molecules predictive of cardiovascular disease. This
led to the identification of the gut microbiota-dependent choline-TMA-TMAO pathway
(see Section 1.5) that is associated with increased risk for cardiovascular disease1, 2. In
order translate this finding into therapeutic utility, one would need to identify ways to
modulate the pathway through either pharmacological interventions or engineering the
gut microbiota. Indeed, one recent study showed that a choline analog, 3,3-dimethyl-1butanol, non-lethally inhibited TMA formation by targeting microbial TMA lyases and
attenuated choline diet-enhanced atherosclerosis in mice3.
To translate our own findings into human biology, we would need to identify and
isolate bacterial taxa from the human gut microbiota that lack urease. Although ASF is
innocuous in mice4, 5, it is part of the commensal murine gut microbiota and cannot be
used for human inoculation. But the absence of urease gene/activity should not be the
only criterion in the development of a humanized version of ASF. One important
consideration is whether ASF contains certain metabolic properties that allow the
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consortium members to coalesce as a functional microbial community – for example, the
exchange of substrates and metabolites in the absence of urease-dependent ammonia
production. At the same time, the factors that make ASF resilient as a microbial
community and exclude the return of other Bacteroidetes in the setting of a normal
protein diet (see Chapter 2) remain to be determined. We found that ASF exhibited
decreased resilience in the setting of a LPD. As such, it is important to understand how
dietary changes affect the stability and resiliency of a therapeutic humanized ASF. We
have developed a pilot human Defined Consortium (hDC) composed of bacterial strains
isolated from the feces of a healthy human subject (Table 4-1). This consortium is
distinct from ASF because it is derived from the
human microbiota and contains taxa distinct from
genera found in ASF. Consortium members were
selected based on the lack of urease gene and
activity

(determined

through

whole

genome

analysis and urease assay testing) and represent
Bacteroidetes, Firmicutes, and Actinobacteria, the
major phyla in human microbiota6, 7. Preliminary
data revealed that hDC inoculation into prepared
Table 4-1. Composition of the
human
Defined
Consortium
(hDC). Phylum names are in left
column, and genera represented
are in right column.

mice corroborates the finding obtained with ASF,
leading to a sustained reduction in fecal ammonia
(Fig. 4-1). Future investigations will need to

address the above considerations and examine the efficacy, resiliency, and safety of
hDC in a murine model of hyperammonemia and hepatic injury before we can consider
the use of a humanized ASF a viable therapeutic option in HE treatment.
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From a basic scientific perspective, we
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Figure 4-1. Fecal ammonia levels
pre- and post-inoculation of hDC into
prepared
conventionally-colonized
mice (n=10, *p<0.05)

superorganism.

Enteric

bacteria utilize ammonia as the preferred
source of nitrogen since ammonia provides
the highest growth rate for bacteria of any

nitrogen source8. Thus, the production of ammonia via urea hydrolysis by bacterial
urease may be a critical component of bacterial nitrogen metabolism, including amino
acid biosynthesis. Based on preliminary data, ASF colonization in mice led to significant
reductions in plasma concentrations of essential amino acids (EAAs) and an increase in
Fischer’s Ratio (valine + leucine + isoleucine) / (phenylalanine + tyrosine) relative to
control mice (Table 4-2). These results suggest that ASF colonization may protect
against morbidity and mortality associated with hepatic injury by altering plasma EAA
levels and the subsequent production of false neurotransmitters via urease-dependent
mechanisms (see Section 1.3). Evidence from the literature supports the notion that the
gut microbiota contributes to protein homeostasis of the mammalian host through
microbial de novo biosynthesis of EAAs. This has been demonstrated in rats9, pigs10,
rabbits11, and humans12. The studies primarily involved the oral administration of an
inorganic

15

N-labeled nitrogen source (e.g.

the detection of

15

15

NH4Cl or

15

N2-urea) to the host followed by

N-labelled amino acids in host tissues, specifically lysine and

threonine. Since lysine and threonine are the only EAAs that do not undergo
transamination in mammalian tissues9, the presence of

15

N-labeled lysine and threonine

indicates synthesis by the gut microbiota and subsequent intestinal absorption by the
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host. The importance of coprophagia was demonstrated in rats, where it was shown that
the utilization of microbial lysine occurred exclusively through coprophagia rather than
direct absorption during initial passage through the GI tract13. In human studies, the
administration of

15

N-compounds to both normal subjects and otherwise healthy subjects

with ileostomies showed that microbial threonine and lysine contributions range from 8 to
17% and 5 to 21%, respectively12, 14. In rats, pigs, and humans, between 1 and 20% of
circulating host plasma lysine, urinary lysine, and body protein lysine of the host are
derived from intestinal microbial sources15. These results demonstrate the importance of
microbial

nitrogen

flux

to

mammalian

host

physiology.

Table 4-2. Plasma concentrations (nmol/mL) of essential amino acids in control and ASF
FMT mice (n = 5 per group, *p<0.05 compared to control, **p<0.01 compared to control).
Values in grey were used to calculate Fischer’s Ratio.

I have designed a series of experiments to examine the impact of bacterial
urease on amino acid metabolism of the gut microbiota and the host through
studies. The oral administration of

15

NH4Cl or

15

15

N flux

N2-urea to 1) control mice, 2) antibiotics-

treated mice, and 3) ASF-transplanted mice followed by quantification of labeled and
unlabeled amino acids in the stool and plasma will help to address some fundamental
questions. For example, how important is the presence of gut microbiota and/or urease
to normal mammalian amino acid homeostasis? Is the reduction in plasma EAAs of
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ASF-colonized mice secondary to decreased microbial synthesis or increased microbial
uptake, namely competition for dietary amino acids with the host? Can urease-negative
bacteria synthesize amino acids at the same capacity as urease-positive bacteria if
given the proper substrate, i.e. ammonia? Preliminary analyses with oral administration
of

15

N2-urea showed significantly higher

15

N enrichment in fecal lysine of control mice

than ASF-transplanted and antibiotics-treated mice (Fig. 4-2). This finding is consistent
with the notion that urea cannot be hydrolyzed and utilized for microbial AA biosynthesis
the

absence

comprehensively

of

urease.

examine

I

the

plan
stool

to
and

plasma amino acid profiles in control, ASFtransplanted, and antibiotics-treated mice to
elucidate the role of bacterial urease in host
and gut microbiota amino acid metabolism.
Future

investigations

importance
metabolic

of

will

bacterial

pathways

of

assess

urease
other

in

the
the

nitrogen

3

APE (atom % excess)

in

2

*

1

*

0
Control +
15
N2-urea
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15
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N2-urea

15

Figure 4-2. 15N enrichment in fecal
lysine after 15N2-urea to control mice,
ASF-transplanted mice, and ABXtreated mice (n=5 per group; *p<0.05
compared to control mice).

compounds including peptides, proteins, neurotransmitters, hormones, purines, and
pyrimidines. This approach will involve both targeted and untargeted proteomics as well
as metabolomics studies, utilizing various approaches including

15

N tracer experiments

and LC/GCMS technologies. Overall, this line of investigation will enable us to better
understand the impact of bacterial urease on host and gut microbiota nitrogen
metabolism, with translational implications for health and disease.
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